The	O
synthesis	O
and	O
pharmacological	O
profile	O
of	O
a	O
series	O
of	O
neuroprotective	O
adenosine	O
agonists	O
are	O
described	O
.	O

Novel	O
A	O
(	O
1	O
)	O
agonists	O
with	O
potent	O
central	O
nervous	O
system	O
effects	O
and	O
diminished	O
influence	O
on	O
the	O
cardiovascular	O
system	O
are	O
reported	O
and	O
compared	O
to	O
selected	O
reference	O
adenosine	O
agonists	O
.	O

The	O
novel	O
compounds	O
featured	O
are	O
derived	O
structurally	O
from	O
two	O
key	O
lead	O
structures	O
:	O
2	B
-	I
chloro	I
-	I
N	I
-	I
(	I
1	I
-	I
phenoxy	I
-	I
2	I
-	I
propyl	I
)	I
adenosine	I
(	O
NNC	B
21	I
-	I
0041	I
,	O
9	O
)	O
and	O
2	B
-	I
chloro	I
-	I
N	I
-	I
(	I
1	I
-	I
piperidinyl	I
)	I
adenosine	I
(	O
NNC	B
,	O
4	O
)	O
.	O

The	O
agonists	O
are	O
characterized	O
in	O
terms	O
of	O
their	O
in	O
vitro	O
profiles	O
,	O
both	O
binding	O
and	O
functional	O
,	O
and	O
in	O
vivo	O
activity	O
in	O
relevant	O
animal	O
models	O
.	O

Neuroprotective	O
properties	O
assessed	O
after	O
postischemic	O
dosing	O
in	O
a	O
Mongolian	O
gerbil	O
severe	O
temporary	O
forebrain	O
ischemia	O
paradigm	O
,	O
using	O
hippocampal	O
CA1	O
damage	O
endpoints	O
,	O
and	O
the	O
efficacy	O
of	O
these	O
agonists	O
in	O
an	O
A	O
(	O
1	O
)	O
functional	O
assay	O
show	O
similarities	O
to	O
some	O
reference	O
adenosine	O
agonists	O
.	O

However	O
,	O
the	O
new	O
compounds	O
we	O
describe	O
exhibit	O
diminished	O
cardiovascular	O
effects	O
in	O
both	O
anesthetized	O
and	O
awake	O
rats	O
when	O
compared	O
to	O
reference	O
A	O
(	O
1	O
)	O
agonists	O
such	O
as	O
(	B
R	I
)	I
-	I
phenylisopropyladenosine	I
(	O
R	B
-	I
PIA	I
,	O
5	O
)	O
,	O
N	B
-	I
cyclopentyladenosine	I
(	O
CPA	B
,	O
2	O
)	O
,	O
4	O
,	O
N	B
-	I
[	I
(	I
1S	I
,	I
trans	I
)	I
-	I
2	I
-	I
hydroxycyclopentyl	I
]	I
adenosine	I
(	O
GR	B
79236	I
,	O
26	O
)	O
,	O
N	B
-	I
cyclohexyl	I
-	I
2	I
'	I
-	I
O	I
-	I
methyladenosine	I
(	O
SDZ	B
WAG	I
994	I
,	O
27	O
)	O
,	O
and	O
N	B
-	I
[	I
(	I
2	I
-	I
methylphenyl	I
)	I
methyl	I
]	I
adenosine	I
(	O
Metrifudil	B
,	O
28	O
)	O
.	O

In	O
mouse	O
permanent	O
middle	O
cerebral	O
artery	O
occlusion	O
focal	O
ischemia	O
,	O
2	B
-	I
chloro	I
-	I
N	I
-	I
[	I
(	I
R	I
)	I
-	I
[	I
(	I
2	I
-	I
benzothiazolyl	I
)	I
thio	I
]	I
-	I
2	I
-	I
propyl	I
]	I
adenosine	I
(	O
NNC	B
21	I
-	I
0136	I
,	O
12	O
)	O
exhibited	O
significant	O
neuroprotection	O
at	O
the	O
remarkably	O
low	O
total	O
intraperitoneal	O
dose	O
of	O
0.1	O
mg	O
/	O
kg	O
,	O
a	O
dose	O
at	O
which	O
no	O
cardiovascular	O
effects	O
are	O
observed	O
in	O
conscious	O
rats	O
.	O

The	O
novel	O
agonists	O
described	O
inhibit	O
6	B
,	I
7	I
-	I
dimethoxy	I
-	I
4	I
-	I
ethyl	I
-	I
beta	I
-	I
carboline	I
-	I
3	I
-	I
carboxylate	I
-	O
induced	O
seizures	O
,	O
and	O
in	O
mouse	O
locomotor	O
activity	O
higher	O
doses	O
are	O
required	O
to	O
reach	O
ED	O
(	O
)	O
values	O
than	O
for	O
reference	O
A	O
(	O
1	O
)	O
agonists	O
.	O

We	O
conclude	O
that	O
two	O
of	O
the	O
novel	O
adenosine	O
derivatives	O
revealed	O
herein	O
,	O
12	O
and	O
5	B
'	I
-	I
deoxy	I
-	I
5	I
'	I
-	I
chloro	I
-	I
N	I
-	I
[	I
4	I
-	I
(	I
phenylthio	I
)	I
-	I
1	I
-	I
piperidinyl	I
]	I
adenosine	I
(	O
NNC	B
21	I
-	I
0147	I
,	O
13	O
)	O
,	O
representatives	O
of	O
a	O
new	O
series	O
of	O
P	O
(	O
1	O
)	O
ligands	O
,	O
reinforce	O
the	O
fact	O
that	O
novel	O
selective	O
adenosine	O
A	O
(	O
1	O
)	O
agonists	O
have	O
potential	O
in	O
the	O
treatment	O
of	O
cerebral	O
ischemia	O
in	O
humans	O
.	O

11358723	O
Influence	O
of	O
estrogens	B
on	O
the	O
androgen	B
metabolism	O
in	O
different	O
subunits	O
of	O
human	O
hair	O
follicles	O
.	O

The	O
molecular	O
pathways	O
involved	O
in	O
estrogen	B
-	O
mediated	O
induction	O
of	O
hair	O
growth	O
in	O
androgenetic	O
alopecia	O
are	O
unknown	O
.	O

Some	O
authors	O
found	O
that	O
estradiol	B
(	O
E	B
)	O
inhibited	O
5alpha	O
-	O
reductase	O
(	O
5alpha	O
-	O
R	O
)	O
activity	O
and	O
therefore	O
we	O
addressed	O
the	O
question	O
whether	O
17alpha	B
-	I
or	O
17beta	B
-	I
E	I
are	O
able	O
to	O
modulate	O
the	O
activity	O
of	O
5alpha	O
-	O
R	O
,	O
3beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
(	O
3beta	O
-	O
HSD	O
)	O
or	O
17beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
(	O
17beta	O
-	O
HSD	O
)	O
in	O
isolated	O
compartments	O
of	O
human	O
hair	O
follicles	O
.	O

For	O
this	O
purpose	O
,	O
scalp	O
biopsies	O
from	O
volunteers	O
were	O
taken	O
and	O
from	O
each	O
biopsy	O
root	O
sheaths	O
,	O
connective	O
tissue	O
sheaths	O
and	O
dermal	O
papillae	O
(	O
DP	O
)	O
were	O
dissected	O
and	O
incubated	O
in	O
the	O
presence	O
of	O
3H	B
-	I
testosterone	I
(	O
T	B
)	O
and	O
,	O
in	O
addition	O
,	O
either	O
17alpha	B
-	I
E	I
,	O
17beta	B
-	I
E	I
,	O
progesterone	B
or	O
finasteride	B
for	O
up	O
to	O
48	O
hrs	O
.	O

Thereafter	O
high	O
-	O
performance	O
liquid	O
chromatography	O
analysis	O
of	O
culture	O
supernatants	O
was	O
performed	O
to	O
detect	O
T	O
-	O
metabolites	O
.	O

At	O
the	O
tested	O
concentrations	O
,	O
finasteride	B
was	O
found	O
to	O
be	O
a	O
major	O
inhibitor	O
of	O
dihydrotestosterone	B
(	O
DHT	B
)	O
formation	O
.	O

Even	O
1	O
nM	O
finasteride	B
inhibited	O
DHT	B
synthesis	O
in	O
DP	O
by	O
86	O
%	O
and	O
1	O
nM	O
progesterone	O
by	O
75	O
%	O
.	O

Estrogens	B
were	O
less	O
able	O
to	O
inhibit	O
the	O
synthesis	O
of	O
DHT	B
in	O
DP	O
(	O
e.g.	O
nM	O
17alpha	B
-	I
E	I
:	O
;	O
nM	O
17beta	B
-	I
E	I
:	O
)	O
.	O

Whether	O
E	B
directly	O
inhibits	O
5alpha	O
-	O
R	O
in	O
DP	O
's	O
or	O
whether	O
the	O
effect	O
of	O
estrogens	B
might	O
be	O
explained	O
by	O
an	O
increased	O
conversion	O
of	O
T	B
to	O
the	O
weaker	O
androgens	B
such	O
as	O
androstendione	B
(	O
via	O
17beta	O
-	O
HSD	O
)	O
,	O
androstenediol	B
(	O
via	O
3beta	O
-	O
HSD	O
)	O
or	O
17beta	B
-	I
E	I
(	O
via	O
aromatase	O
)	O
,	O
thereby	O
diminishing	O
the	O
amount	O
of	O
T	B
available	O
for	O
the	O
conversion	O
to	O
DHT	B
,	O
remains	O
to	O
be	O
shown	O
.	O

Diphenol	B
activation	O
of	O
the	O
monophenolase	O
and	O
diphenolase	O
activities	O
of	O
field	O
bean	O
(	O
Dolichos	O
lablab	O
)	O
polyphenol	O
oxidase	O
.	O

This	O
paper	O
reports	O
a	O
study	O
on	O
the	O
hydroxylation	O
of	O
ferulic	B
acid	I
and	O
tyrosine	B
by	O
field	O
bean	O
(	O
Dolichos	O
lablab	O
)	O
polyphenol	O
oxidase	O
,	O
a	O
reaction	O
that	O
does	O
not	O
take	O
place	O
without	O
the	O
addition	O
of	O
catechol	B
.	O

A	O
lag	O
period	O
similar	O
to	O
the	O
characteristic	O
lag	O
of	O
tyrosinase	O
activity	O
was	O
observed	O
,	O
the	O
length	O
of	O
which	O
decreased	O
with	O
increasing	O
catechol	B
concentration	O
and	O
increased	O
with	O
increasing	O
ferulic	B
acid	I
concentration	O
.	O

The	O
activation	O
constant	O
K	O
(	O
a	O
)	O
of	O
catechol	B
for	O
ferulic	B
acid	I
hydroxylation	O
reaction	O
was	O
5	O
mM	O
.	O

The	O
kinetic	O
parameters	O
of	O
field	O
bean	O
polyphenol	O
oxidase	O
toward	O
ferulic	B
acid	I
and	O
tyrosine	B
were	O
evaluated	O
in	O
the	O
presence	O
of	O
catechol	B
.	O

4	B
-	I
Methyl	I
catechol	I
,	O
L	B
-	I
dihydroxyphenylalanine	I
,	O
pyrogallol	B
,	O
and	O
2,3,4	B
-	I
trihydroxybenzoic	I
acid	I
,	O
substrates	O
with	O
high	O
binding	O
affinity	O
to	O
field	O
bean	O
polyphenol	O
oxidase	O
,	O
could	O
stimulate	O
this	O
hydroxylation	O
reaction	O
.	O

In	O
contrast	O
,	O
diphenols	B
such	O
as	O
protocatechuic	B
acid	I
,	O
gallic	B
acid	I
,	O
chlorogenic	B
acid	I
,	O
and	O
caffeic	B
acid	I
,	O
which	O
were	O
not	O
substrates	O
for	O
the	O
oxidation	O
reaction	O
,	O
were	O
unable	O
to	O
bring	O
about	O
this	O
activation	O
.	O

It	O
is	O
most	O
likely	O
that	O
only	O
o	B
-	I
diphenols	I
that	O
are	O
substrates	O
for	O
the	O
diphenolase	O
serve	O
as	O
cosubstrates	O
by	O
donating	O
electrons	O
at	O
the	O
active	O
site	O
for	O
the	O
monophenolase	O
activity	O
.	O

The	O
reaction	O
mechanism	O
for	O
this	O
activation	O
is	O
consistent	O
with	O
that	O
proposed	O
for	O
tyrosinase	O
(	O
Sanchez	O
-	O
Ferrer	O
,	O
A	O
.	O
;	O
Rodriguez	O
-	O
Lopez	O
,	O
J	O
.	O

N	O
.	O
;	O
Garcia	O
-	O
Canovas	O
,	O
F	O
.	O
;	O
Garcia	O
-	O
Carmona	O
,	O
F	O
.	O

Biochim	O
.	O

Biophys	O
.	O

Acta	O
1995	O
,	O
1247	O
,	O
1	O
-	O
11	O
)	O
.	O

The	O
presence	O
of	O
o	B
-	I
diphenols	I
,	O
viz	O
.	O

catechol	B
,	O
L	B
-	I
dihydroxyphenylalanine	I
,	O
and	O
4	B
-	I
methyl	I
catechol	I
,	O
is	O
also	O
necessary	O
for	O
the	O
oxidation	O
of	O
the	O
diphenols	B
,	O
caffeic	B
acid	I
,	O
and	O
catechin	B
to	O
their	O
quinones	B
by	O
the	O
field	O
bean	O
polyphenol	O
oxidase	O
.	O

This	O
oxidation	O
reaction	O
occurs	O
immediately	O
with	O
no	O
lag	O
period	O
and	O
does	O
not	O
occur	O
without	O
the	O
addition	O
of	O
diphenol	B
.	O

The	O
kinetic	O
parameters	O
for	O
caffeic	B
acid	I
(	O
K	O
(	O
m	O
)	O
=	O
0.08	O
mM	O
,	O
V	O
(	O
max	O
)	O
=	O
u	O
/	O
mg	O
)	O
in	O
the	O
presence	O
of	O
catechol	B
and	O
the	O
activation	O
constant	O
K	O
(	O
a	O
)	O
of	O
catechol	B
(	O
4.6	O
mM	O
)	O
for	O
this	O
reaction	O
were	O
enumerated	O
.	O

The	O
absence	O
of	O
a	O
lag	O
period	O
for	O
this	O
reaction	O
indicates	O
that	O
the	O
diphenol	B
mechanism	O
of	O
diphenolase	O
activation	O
differs	O
from	O
the	O
way	O
in	O
which	O
the	O
same	O
o	B
-	I
diphenols	I
activate	O
the	O
monophenolase	O
activity	O
.	O

Attenuation	O
of	O
glucocorticoid	B
functions	O
in	O
an	O
Anx	O
-	O
A1	O
-	O
/	O
-	O
cell	O
line	O
.	O

The	O
Ca	O
(	O
2	O
+	O
)	O
-	O
and	O
phospholipid	O
-	O
binding	O
protein	O
Anx	O
-	O
A1	O
(	O
annexin	O
1	O
;	O
lipocortin	O
1	O
)	O
has	O
been	O
described	O
both	O
as	O
an	O
inhibitor	O
of	O
phospholipase	O
A	O
(	O
2	O
)	O
(	O
PLA	O
(	O
2	O
)	O
)	O
activity	O
and	O
as	O
a	O
mediator	O
of	O
glucocorticoid	B
-	O
regulated	O
cell	O
growth	O
and	O
eicosanoid	B
generation	O
.	O

Here	O
we	O
show	O
that	O
,	O
when	O
compared	O
with	O
Anx	O
-	O
A1	O
(	O
+	O
/	O
+	O
)	O
cells	O
,	O
lung	O
fibroblast	O
cell	O
lines	O
derived	O
from	O
the	O
Anx	O
-	O
A1	O
(	O
-	O
/	O
-	O
)	O
mouse	O
exhibit	O
an	O
altered	O
morphology	O
characterized	O
by	O
a	O
spindle	O
-	O
shaped	O
appearance	O
and	O
an	O
accumulation	O
of	O
intracellular	O
organelles	O
.	O

Unlike	O
their	O
wild	O
-	O
type	O
counterparts	O
,	O
Anx	O
-	O
A1	O
(	O
-	O
/	O
-	O
)	O
cells	O
also	O
overexpress	O
cyclo	O
-	O
oxygenase	O
2	O
(	O
COX	O
2	O
)	O
,	O
cytosolic	O
PLA	O
(	O
2	O
)	O
and	O
secretory	O
PLA	O
(	O
2	O
)	O
and	O
in	O
response	O
to	O
fetal	O
calf	O
serum	O
,	O
exhibit	O
an	O
exaggerated	O
release	O
of	O
eicosanoids	B
,	O
which	O
is	O
insensitive	O
to	O
dexamethasone	B
(	O
(	O
-	O
8	O
)	O
-	O
(	O
-	O
6	O
)	O
M	O
)	O
inhibition	O
.	O

Proliferation	O
and	O
serum	O
-	O
induced	O
progression	O
of	O
Anx	O
-	O
A1	O
(	O
+	O
/	O
+	O
)	O
cells	O
from	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
into	O
S	O
phase	O
,	O
and	O
the	O
associated	O
expression	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
2	O
(	O
ERK2	O
)	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
4	O
(	O
cdk4	O
)	O
and	O
COX	O
2	O
,	O
is	O
strongly	O
inhibited	O
by	O
dexamethasone	O
,	O
whereas	O
Anx	O
-	O
A1	O
(	O
-	O
/	O
-	O
)	O
cells	O
are	O
refractory	O
to	O
the	O
drug	O
.	O

Loss	O
of	O
the	O
response	O
to	O
dexamethasone	B
in	O
Anx	O
-	O
A1	O
(	O
-	O
/	O
-	O
)	O
cells	O
occurs	O
against	O
a	O
background	O
of	O
no	O
apparent	O
change	O
in	O
glucocorticoid	O
receptor	O
expression	O
or	O
sensitivity	O
to	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
strongly	O
that	O
Anx	O
-	O
A1	O
functions	O
as	O
an	O
inhibitor	O
of	O
signal	O
-	O
transduction	O
pathways	O
that	O
lead	O
to	O
cell	O
proliferation	O
and	O
may	O
help	O
to	O
explain	O
how	O
glucocorticoids	B
regulate	O
these	O
processes	O
.	O

1512594	O
Genetic	O
absence	O
epilepsy	O
in	O
rats	O
from	O
Strasbourg	O
-	O
-	O
a	O
review	O
.	O

We	O
have	O
selected	O
a	O
strain	O
of	O
rats	O
and	O
designated	O
it	O
the	O
Genetic	O
Absence	O
Epilepsy	O
Rat	O
from	O
Strasbourg	O
(	O
GAERS	O
)	O
.	O

In	O
this	O
strain	O
,	O
of	O
the	O
animals	O
present	O
recurrent	O
generalized	O
non	O
-	O
convulsive	O
seizures	O
characterized	O
by	O
bilateral	O
and	O
synchronous	O
spike	O
-	O
and	O
-	O
wave	O
discharges	O
accompanied	O
with	O
behavioural	O
arrest	O
,	O
staring	O
and	O
sometimes	O
twitching	O
of	O
the	O
vibrissae	O
.	O

Spontaneous	O
SWD	O
(	O
7	O
-	O
11	O
cps	O
,	O
microV	O
,	O
0.5	O
-	O
75	O
sec	O
)	O
start	O
and	O
end	O
abruptly	O
on	O
a	O
normal	O
background	O
EEG	O
.	O

They	O
usually	O
occur	O
at	O
a	O
mean	O
frequency	O
of	O
1.5	O
per	O
min	O
when	O
the	O
animals	O
are	O
in	O
a	O
state	O
of	O
quiet	O
wakefulness	O
.	O

Drugs	O
effective	O
against	O
absence	O
seizures	O
in	O
humans	O
(	O
ethosuccimide	B
,	O
trimethadione	B
,	O
valproate	B
,	O
benzodiazepines	B
)	O
suppress	O
the	O
SWD	O
dose	O
-	O
dependently	O
,	O
whereas	O
drugs	O
specific	O
for	O
convulsive	O
or	O
focal	O
seizures	O
(	O
carbamazepine	B
,	O
phenytoin	B
)	O
are	O
ineffective	O
.	O

SWD	O
are	O
increased	O
by	O
epileptogenic	O
drugs	O
inducing	O
petit	O
mal	O
-	O
like	O
seizures	O
,	O
such	O
as	O
pentylenetetrazol	B
,	O
gamma	B
-	I
hydroxybutyrate	I
,	O
THIP	B
and	O
penicillin	B
.	O

Depth	O
EEG	O
recordings	O
and	O
lesion	O
experiments	O
show	O
that	O
SWD	O
in	O
GAERs	O
depend	O
on	O
cortical	O
and	O
thalamic	O
structures	O
with	O
a	O
possible	O
rhythmic	O
triggering	O
by	O
the	O
lateral	O
thalamus	O
.	O

Most	O
neurotransmitters	O
are	O
involved	O
in	O
the	O
control	O
of	O
SWD	O
(	O
dopamine	B
,	O
noradrenaline	B
,	O
NMDA	B
,	O
acetylcholine	B
)	O
,	O
but	O
GABA	B
and	O
gamma	B
-	I
hydroxybutyrate	I
(	O
GHB	B
)	O
seem	O
to	O
play	O
a	O
critical	O
role	O
.	O

SWD	O
are	O
genetically	O
determined	O
with	O
an	O
autosomal	O
dominant	O
inheritance	O
.	O

The	O
variable	O
expression	O
of	O
SWD	O
in	O
offsprings	O
from	O
GAERS	O
x	O
control	O
reciprocal	O
crosses	O
may	O
be	O
due	O
to	O
the	O
existence	O
of	O
multiple	O
genes	O
.	O

Neurophysiological	O
,	O
behavioural	O
,	O
pharmacological	O
and	O
genetic	O
studies	O
demonstrate	O
that	O
spontaneous	O
SWD	O
in	O
GAERS	O
fulfill	O
all	O
the	O
requirements	O
for	O
an	O
experimental	O
model	O
of	O
absence	O
epilepsy	O
.	O

As	O
the	O
mechanisms	O
underlying	O
absence	O
epilepsy	O
in	O
humans	O
are	O
still	O
unknown	O
,	O
the	O
analysis	O
of	O
the	O
genetic	O
thalamocortical	O
dysfunction	O
in	O
GAERS	O
may	O
be	O
fruitful	O
in	O
investigations	O
of	O
the	O
pathogenesis	O
of	O
generalized	O
non	O
-	O
convulsive	O
seizures	O
.	O

Predictive	O
clinical	O
parameters	O
for	O
therapeutic	O
efficacy	O
of	O
rosiglitazone	B
in	O
Korean	O
type	O
2	O
diabetes	O
mellitus	O
.	O

This	O
study	O
evaluated	O
the	O
efficacy	O
of	O
rosiglitazone	B
in	O
non	O
-	O
obese	O
and	O
obese	O
Korean	O
type	O
2	O
diabetic	O
patients	O
of	O
long	O
duration	O
.	O

A	O
total	O
of	O
125	O
patients	O
(	O
M	O
:	O
F	O
=	O
44	O
:	O
81	O
,	O
mean	O
age	O
:	O
58.4	O
+	O
/	O
-	O
9.1	O
years	O
,	O
BMI	O
:	O
24.2	O
+	O
/	O
-	O
2.7	O
kg	O
/	O
m2	O
,	O
duration	O
of	O
diabetes	O
:	O
11.0	O
+	O
/	O
-	O
6.4	O
years	O
)	O
were	O
randomly	O
allocated	O
to	O
12	O
weeks	O
of	O
rosiglitazone	B
treatment	O
(	O
4	O
mg	O
per	O
day	O
)	O
or	O
a	O
control	O
group	O
.	O

Responders	O
were	O
defined	O
as	O
patients	O
who	O
experienced	O
fasting	O
plasma	O
glucose	B
(	O
FPG	O
)	O
reduction	O
of	O
>	O
or	O
HbA1c	O
reduction	O
of	O
>	O
1	O
(	O
%	O
)	O
.	O

Rosiglitazone	B
significantly	O
improved	O
glycemic	O
control	O
by	O
reducing	O
FPG	O
and	O
HbA1c	O
(	O
-	O
3.4	O
mmol	O
/	O
l	O
and	O
-	O
1.1	O
%	O
,	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

It	O
also	O
significantly	O
increased	O
HOMA	O
(	O
beta	O
-	O
cell	O
function	O
)	O
(	O
+	O
9.7	O
,	O
P	O
<	O
0.01	O
)	O
and	O
QUICKI	O
(	O
+	O
0.029	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
decreased	O
HOMA	O
(	O
IR	O
)	O
(	O
-	O
1.73	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Females	O
and	O
those	O
with	O
higher	O
waist	O
-	O
hip	O
ratio	O
made	O
up	O
a	O
greater	O
portion	O
of	O
rosiglitazone	O
-	O
responders	O
.	O

Responders	O
(	O
45	O
patients	O
,	O
75	O
%	O
)	O
also	O
showed	O
significantly	O
higher	O
FPG	O
,	O
HbA1c	O
,	O
systolic	O
blood	O
pressures	O
,	O
fasting	O
insulin	O
levels	O
and	O
HOMA	O
(	O
IR	O
)	O
,	O
and	O
lower	O
QUICKI	O
than	O
nonresponders	O
.	O

Among	O
these	O
parameters	O
of	O
responders	O
,	O
waist	O
-	O
hip	O
ratio	O
of	O
non	O
-	O
obese	O
subgroup	O
,	O
initial	O
glycemic	O
control	O
of	O
obese	O
subgroup	O
,	O
and	O
systolic	O
blood	O
pressure	O
of	O
both	O
subgroups	O
lost	O
their	O
significance	O
after	O
subdivision	O
analysis	O
.	O

However	O
,	O
the	O
baseline	O
HOMA	O
(	O
IR	O
)	O
and	O
QUICKI	O
were	O
significantly	O
correlated	O
with	O
the	O
response	O
rate	O
to	O
rosiglitazone	B
.	O

Moreover	O
,	O
in	O
multiple	O
logistic	O
regression	O
analysis	O
,	O
HOMA	O
(	O
IR	O
)	O
and	O
QUICKI	O
retained	O
their	O
significance	O
as	O
the	O
independent	O
predictors	O
.	O

Even	O
in	O
Korean	O
type	O
2	O
diabetic	O
patients	O
of	O
long	O
duration	O
but	O
with	O
relatively	O
preserved	O
beta	O
-	O
cell	O
function	O
,	O
rosiglitazone	O
improved	O
glycemic	O
control	O
,	O
insulin	O
sensitivity	O
,	O
and	O
beta	O
-	O
cell	O
function	O
.	O

In	O
this	O
ethnic	O
group	O
,	O
female	O
gender	O
,	O
central	O
obesity	O
,	O
and	O
especially	O
severe	O
insulin	O
resistance	O
were	O
identified	O
as	O
predictive	O
clinical	O
parameters	O
of	O
rosiglitazone	B
-	O
responders	O
.	O

15652357	O
Identification	O
of	O
MAGI	O
-	O
3	O
as	O
a	O
transforming	O
growth	O
factor	O
-	O
alpha	O
tail	O
binding	O
protein	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
alpha	O
precursor	O
(	O
proTGFalpha	O
)	O
contains	O
a	O
C	O
-	O
terminal	O
PSD	O
-	O
95	O
/	O
SAP90	O
,	O
Discs	O
Large	O
,	O
and	O
Zona	O
Occludens	O
-	O
1	O
(	O
PDZ	O
)	O
recognition	O
motif	O
(	O
TVV	O
)	O
.	O

By	O
yeast	O
two	O
-	O
hybrid	O
screening	O
of	O
a	O
mouse	O
embryo	O
library	O
,	O
we	O
have	O
found	O
that	O
a	O
third	O
member	O
of	O
a	O
family	O
of	O
PDZ	O
-	O
containing	O
proteins	O
,	O
membrane	O
associated	O
guanylate	O
kinase	O
inverted	O
-	O
3	O
(	O
MAGI	O
-	O
3	O
)	O
,	O
binds	O
to	O
TGFalpha	O
's	O
TVV	O
.	O

MAGI	O
-	O
3	O
is	O
widely	O
expressed	O
in	O
multiple	O
mouse	O
tissues	O
,	O
including	O
brain	O
.	O

Immunolocalization	O
showed	O
that	O
MAGI	O
-	O
3	O
and	O
TGFalpha	O
were	O
colocalized	O
in	O
neurons	O
in	O
the	O
cortex	O
and	O
dentate	O
gyrus	O
,	O
as	O
well	O
as	O
in	O
ependymal	O
cells	O
and	O
some	O
astrocytes	O
.	O

In	O
vitro	O
,	O
proTGFalpha	O
bound	O
the	O
PDZ	O
-	O
1	O
domain	O
of	O
MAGI	O
-	O
3	O
and	O
MAGI	O
-	O
2	O
,	O
but	O
not	O
MAGI	O
-	O
1	O
.	O

MAGI	O
-	O
3	O
and	O
the	O
17	O
-	O
kDa	O
cell	O
surface	O
form	O
of	O
proTGFalpha	O
interact	O
transiently	O
in	O
MDCK	O
cells	O
stably	O
transfected	O
with	O
both	O
MAGI	O
-	O
3	O
and	O
human	O
proTGFalpha	O
cDNAs	O
.	O

MAGI	O
-	O
3	O
and	O
wild	O
-	O
type	O
proTGFalpha	O
colocalize	O
at	O
the	O
cell	O
surface	O
.	O

In	O
contrast	O
,	O
MAGI	O
-	O
3	O
forms	O
a	O
stable	O
complex	O
with	O
membrane	O
-	O
fixed	O
TGFalpha	O
early	O
in	O
the	O
secretory	O
pathway	O
and	O
interacts	O
with	O
immature	O
and	O
cell	O
surface	O
forms	O
of	O
membrane	O
-	O
fixed	O
TGFalpha	O
.	O

Overexpression	O
of	O
MAGI	O
-	O
3	O
resulted	O
in	O
increased	O
levels	O
of	O
TGFalpha	O
in	O
the	O
basolateral	O
medium	O
of	O
polarized	O
MDCK	O
cells	O
,	O
suggesting	O
that	O
MAGI	O
-	O
3	O
has	O
a	O
role	O
in	O
efficient	O
trafficking	O
of	O
TGFalpha	O
to	O
the	O
cell	O
surface	O
in	O
polarized	O
epithelial	O
cells	O
.	O

Sulfur	O
-	O
bridged	O
pregnanes	O
6,19	B
-	I
epithioprogesterone	I
,	O
21	B
-	I
hydroxy	I
-	I
6,19	I
-	I
epithioprogesterone	I
,	O
and	O
the	O
corresponding	O
sulfoxides	B
and	O
sulfones	B
were	O
synthesized	O
and	O
tested	O
as	O
blockers	O
of	O
the	O
immunosuppresive	O
activity	O
of	O
dexamethasone	B
in	O
rat	O
thymocytes	O
.	O

A	O
new	O
one	O
-	O
pot	O
procedure	O
is	O
described	O
for	O
the	O
preparation	O
of	O
6,19	B
-	I
epithioprogesterone	I
and	O
related	O
compounds	O
by	O
iodocyclization	O
of	O
a	O
19	B
-	I
sulfanylpregn	I
-	I
5	I
-	I
ene	I
.	O

Antiimmunosuppresive	O
activity	O
was	O
evaluated	O
by	O
the	O
ability	O
of	O
the	O
different	O
steroids	O
to	O
block	O
dexamethasone	B
-	O
mediated	O
apoptosis	O
in	O
thymocytes	O
and	O
dexamethasone	B
-	O
mediated	O
inhibition	O
of	O
the	O
NFkappa	O
-	O
B	O
transcription	O
factor	O
activity	O
.	O

DNA	O
fragmentation	O
and	O
annexin	O
V	O
-	O
FITC	O
positive	O
cells	O
were	O
taken	O
as	O
parameters	O
of	O
apoptosis	O
whereas	O
NFkappa	O
-	O
B	O
activity	O
was	O
tested	O
by	O
the	O
expression	O
of	O
the	O
reporter	O
vector	O
kappaB	O
-	O
luciferase	O
by	O
TNF	O
-	O
alpha	O
in	O
Hela	O
cells	O
.	O

21	B
-	I
Hydroxy	I
-	I
6,19	I
-	I
epithioprogesterone	I
S	I
,	I
S	I
-	I
dioxide	I
had	O
improved	O
activity	O
in	O
both	O
parameters	O
,	O
while	O
21	B
-	I
hydroxy	I
-	I
6,19	I
-	I
epithioprogesterone	I
had	O
improved	O
activity	O
only	O
in	O
blocking	O
dexamethasone	B
-	O
induced	O
programmed	O
cell	O
death	O
.	O

[	O
Method	O
of	O
determination	O
of	O
biogenic	O
amines	B
in	O
wines	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
with	O
fluorescence	O
detector	O
and	O
ultraviolet	O
detector	O
]	O
OBJECTIVE	O
:	O
A	O
pre	O
-	O
column	O
derivation	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
method	O
was	O
developed	O
for	O
the	O
determination	O
of	O
biogenic	O
amines	O
(	O
tryptamine	B
,	O
phenylethyamine	B
,	O
putrescine	B
,	O
cadaverine	B
,	O
histamine	B
,	O
tyramine	B
,	O
spermidine	B
,	O
and	O
spermine	B
)	O
in	O
wines	O
with	O
fluorescecse	O
detector	O
(	O
FLD	O
)	O
and	O
ultraviolet	O
detector	O
(	O
UVD	O
)	O
.	O

METHODS	O
:	O
Liqiud	O
-	O
liqiud	O
extraction	O
(	O
LLE	O
)	O
was	O
used	O
to	O
clean	O
up	O
wine	O
samples	O
with	O
chloroform	B
/	O
butanol	B
prior	O
to	O
derivatization	O
with	O
dansyl	B
chloride	I
,	O
biogenic	O
amines	O
were	O
separated	O
using	O
gradient	O
elution	O
.	O

Mobile	O
phase	O
A	O
was	O
methanol	O
and	O
mobile	O
phase	O
B	O
was	O
water	O
with	O
the	O
flow	O
rate	O
1.5	O
ml	O
/	O
min	O
.	O

The	O
column	O
used	O
was	O
a	O
CAPCELL	O
PAK	O
C18	O
MG	O
(	O
4.6	O
mm	O
I	O
.	O

D	O
.	O

x	O
mm	O
,	O
5	O
microm	O
)	O
and	O
gradient	O
elution	O
at	O
constant	O
column	O
tempereture	O
with	O
degrees	O
C	O
under	O
fluorescence	O
detector	O
with	O
Ex	O
and	O
Em	O
,	O
The	O
method	O
and	O
ultraviolet	O
detector	O
with	O
254	O
nm	O
.	O

1,7	B
-	I
Diaminoheptane	I
was	O
used	O
as	O
the	O
internal	O
standard	O
(	O
IS	O
)	O
.	O

RESULTS	O
:	O
was	O
linear	O
for	O
the	O
amines	O
studied	O
at	O
concentration	O
ranging	O
from	O
0.05	O
to	O
25	O
mg	O
/	O
L	O
,	O
except	O
for	O
spermidine	B
and	O
spermine	B
,	O
which	O
ranging	O
from	O
0.05	O
to	O
15	O
mg	O
/	O
L	O
.	O

The	O
average	O
recoveries	O
ranged	O
from	O
79.2	O
%	O
to	O
127.5	O
%	O
for	O
all	O
amines	O
,	O
The	O
RSDs	O
were	O
less	O
than	O
.	O

With	O
this	O
method	O
,	O
5	O
wine	O
samples	O
were	O
determined	O
,	O
the	O
results	O
were	O
favorable	O
.	O

CONCLUTION	O
:	O
method	O
can	O
be	O
applied	O
for	O
determination	O
of	O
biogenic	O
amines	O
in	O
wines	O
.	O

16682228	O
Heterologous	O
expression	O
of	O
lipoprotein	O
-	O
associated	O
phospholipase	O
A2	O
in	O
different	O
expression	O
systems	O
.	O

Lipoprotein	O
-	O
associated	O
phospholipase	O
A	O
(	O
2	O
)	O
(	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
)	O
is	O
a	O
key	O
enzyme	O
involved	O
in	O
atherosclerosis	O
,	O
and	O
has	O
been	O
considered	O
as	O
a	O
new	O
target	O
for	O
drug	O
discovery	O
.	O

The	O
major	O
difficulty	O
for	O
high	O
-	O
throughput	O
screening	O
of	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
inhibitors	O
and	O
for	O
functional	O
studies	O
was	O
their	O
fast	O
and	O
efficient	O
production	O
.	O

Purification	O
of	O
native	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
from	O
human	O
plasma	O
was	O
complicated	O
and	O
produced	O
a	O
very	O
low	O
yield	O
.	O

We	O
herein	O
examined	O
the	O
feasibility	O
of	O
expressing	O
and	O
purifying	O
recombinant	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
in	O
different	O
heterologous	O
expression	O
systems	O
.	O

The	O
fusion	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
was	O
expressed	O
at	O
high	O
levels	O
and	O
exhibited	O
strong	O
enzyme	O
activity	O
in	O
insect	O
cell	O
-	O
baculovirus	O
expression	O
system	O
.	O

The	O
functional	O
enzyme	O
could	O
also	O
be	O
produced	O
in	O
Pichia	O
pastoris	O
.	O

The	O
inclusion	O
of	O
a	O
Kozak	O
sequence	O
increased	O
greatly	O
the	O
expression	O
level	O
of	O
recombinant	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
in	O
insect	O
cells	O
,	O
but	O
had	O
little	O
effect	O
on	O
the	O
expression	O
of	O
recombinant	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
in	O
P	O
.	O

pastoris	O
and	O
Escherichia	O
coli	O
.	O

P	O
.	O

pastoris	O
-	O
produced	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
could	O
be	O
purified	O
rapidly	O
and	O
conveniently	O
through	O
a	O
one	O
-	O
step	O
procedure	O
,	O
while	O
baculovirus	O
-	O
produced	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
could	O
be	O
efficiently	O
purified	O
through	O
a	O
two	O
-	O
step	O
procedure	O
.	O

This	O
ability	O
to	O
readily	O
produce	O
recombinant	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
could	O
provide	O
a	O
screening	O
model	O
for	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
inhibitors	O
and	O
will	O
facilitate	O
further	O
studies	O
on	O
this	O
enzyme	O
.	O

A	O
neural	O
network	O
-	O
based	O
method	O
for	O
risk	O
factor	O
analysis	O
of	O
West	O
Nile	O
virus	O
.	O

There	O
is	O
a	O
lack	O
of	O
knowledge	O
about	O
which	O
risk	O
factors	O
are	O
more	O
important	O
in	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
transmission	O
and	O
risk	O
magnitude	O
.	O

A	O
better	O
understanding	O
of	O
the	O
risk	O
factors	O
is	O
of	O
great	O
help	O
in	O
developing	O
effective	O
new	O
technologies	O
and	O
appropriate	O
prevention	O
strategies	O
for	O
WNV	O
infection	O
.	O

A	O
contribution	O
analysis	O
of	O
all	O
risk	O
factors	O
in	O
WNV	O
infection	O
would	O
identify	O
those	O
major	O
risk	O
factors	O
.	O

Based	O
on	O
the	O
identified	O
major	O
risk	O
factors	O
,	O
measures	O
to	O
control	O
WNV	O
proliferation	O
could	O
be	O
directed	O
toward	O
those	O
significant	O
risk	O
factors	O
,	O
thus	O
improving	O
the	O
effectiveness	O
and	O
efficiency	O
in	O
developing	O
WNV	O
control	O
and	O
prevention	O
strategies	O
.	O

Neural	O
networks	O
have	O
many	O
generally	O
accepted	O
advantages	O
over	O
conventional	O
analytical	O
techniques	O
,	O
for	O
instance	O
,	O
ability	O
to	O
automatically	O
learn	O
the	O
relationship	O
between	O
the	O
inputs	O
and	O
outputs	O
from	O
training	O
data	O
,	O
powerful	O
generalization	O
ability	O
,	O
and	O
capability	O
of	O
handling	O
nonlinear	O
interactions	O
.	O

In	O
this	O
article	O
,	O
a	O
neural	O
network	O
model	O
was	O
developed	O
for	O
analysis	O
of	O
risk	O
factors	O
in	O
WNV	O
infection	O
.	O

To	O
reveal	O
the	O
relative	O
contribution	O
of	O
the	O
input	O
variables	O
,	O
the	O
neural	O
network	O
was	O
trained	O
using	O
an	O
algorithm	O
called	O
structural	O
learning	O
with	O
forgetting	O
.	O

During	O
the	O
learning	O
,	O
weak	O
neural	O
connections	O
are	O
forced	O
to	O
fade	O
away	O
while	O
a	O
skeletal	O
network	O
with	O
strong	O
connections	O
emerges	O
.	O

The	O
significant	O
risk	O
factors	O
can	O
be	O
identified	O
by	O
analyzing	O
this	O
skeletal	O
network	O
.	O

The	O
proposed	O
approach	O
is	O
tested	O
with	O
the	O
dead	O
bird	O
surveillance	O
data	O
in	O
Ontario	O
,	O
Canada	O
.	O

The	O
results	O
demonstrate	O
the	O
effectiveness	O
of	O
the	O
proposed	O
approach	O
.	O

Households	O
'	O
perceived	O
personal	O
risk	O
and	O
responses	O
in	O
a	O
multihazard	O
environment	O
.	O

This	O
study	O
proposed	O
and	O
tested	O
a	O
multistage	O
model	O
of	O
household	O
response	O
to	O
three	O
hazards	O
-	O
flood	O
,	O
hurricane	O
,	O
and	O
toxic	O
chemical	O
release	O
-	O
in	O
Harris	O
County	O
Texas	O
.	O

The	O
model	O
,	O
which	O
extends	O
Lindell	O
and	O
Perry	O
's	O
(	O
1992	O
,	O
)	O
Protective	O
Action	O
Decision	O
Model	O
,	O
proposed	O
a	O
basic	O
causal	O
chain	O
from	O
hazard	O
proximity	O
through	O
hazard	O
experience	O
and	O
perceived	O
personal	O
risk	O
to	O
expectations	O
of	O
continued	O
residence	O
in	O
the	O
home	O
and	O
adoption	O
of	O
household	O
hazard	O
adjustments	O
.	O

Data	O
from	O
321	O
households	O
generally	O
supported	O
the	O
model	O
,	O
but	O
the	O
mediating	O
effects	O
of	O
hazard	O
experience	O
and	O
perceived	O
personal	O
risk	O
were	O
partial	O
rather	O
than	O
complete	O
.	O

In	O
addition	O
,	O
the	O
data	O
suggested	O
that	O
four	O
demographic	O
variables	O
-	O
gender	O
,	O
age	O
,	O
income	O
,	O
and	O
ethnicity	O
-	O
affect	O
the	O
basic	O
causal	O
chain	O
at	O
different	O
points	O
.	O

Prospects	O
for	O
the	O
use	O
of	O
differentiation	O
-	O
modulating	O
agents	O
as	O
adjuvant	O
of	O
photodynamic	O
therapy	O
for	O
proliferative	O
dermatoses	O
.	O

Current	O
interest	O
in	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
in	O
dermatology	O
stems	O
from	O
its	O
recognized	O
success	O
in	O
dermatological	O
oncology	O
,	O
straightforward	O
approach	O
,	O
easy	O
accessibility	O
and	O
low	O
cost	O
.	O

PDT	O
is	O
a	O
photochemistry	O
-	O
based	O
modality	O
in	O
which	O
a	O
light	O
-	O
activated	O
photosensitizer	O
(	O
PS	O
)	O
destroys	O
tissue	O
through	O
oxygen	O
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O

Although	O
PDT	O
has	O
been	O
used	O
in	O
dermatology	O
for	O
several	O
decades	O
,	O
its	O
application	O
has	O
still	O
not	O
extended	O
significantly	O
into	O
the	O
routine	O
management	O
of	O
neoplastic	O
and	O
proliferative	O
dermatoses	O
because	O
of	O
continuing	O
issues	O
with	O
the	O
selectivity	O
of	O
the	O
PS	O
for	O
affected	O
tissues	O
.	O

This	O
review	O
analyzes	O
prospects	O
for	O
optimization	O
of	O
PDT	O
for	O
the	O
management	O
of	O
dermatoses	O
with	O
defects	O
in	O
keratinocyte	O
proliferation	O
/	O
differentiation	O
,	O
and	O
discusses	O
the	O
use	O
of	O
differentiating	O
agents	O
that	O
redirect	O
metabolic	O
utilization	O
within	O
cells	O
and	O
lead	O
to	O
high	O
levels	O
of	O
PS	O
accumulation	O
.	O

Distinct	O
cognitive	O
profiles	O
and	O
rates	O
of	O
decline	O
on	O
the	O
Mattis	O
Dementia	O
Rating	O
Scale	O
in	O
autopsy	O
-	O
confirmed	O
frontotemporal	O
dementia	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Neuropsychological	O
studies	O
have	O
shown	O
that	O
patients	O
with	O
Frontotemporal	O
dementia	O
(	O
FTD	O
)	O
perform	O
worse	O
than	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
on	O
tests	O
of	O
conceptualization	O
and	O
verbal	O
fluency	O
,	O
but	O
better	O
on	O
tests	O
of	O
memory	O
and	O
visuospatial	O
functions	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
these	O
distinct	O
cognitive	O
profiles	O
are	O
robust	O
enough	O
to	O
be	O
detected	O
using	O
a	O
relatively	O
brief	O
dementia	O
screening	O
instrument	O
such	O
as	O
the	O
Mattis	O
Dementia	O
Rating	O
Scale	O
(	O
MDRS	O
)	O
.	O

To	O
address	O
this	O
issue	O
,	O
the	O
MDRS	O
subscale	O
profiles	O
of	O
patients	O
with	O
autopsy	O
-	O
confirmed	O
FTD	O
(	O
n	O
=	O
17	O
)	O
or	O
AD	O
(	O
n	O
=	O
34	O
)	O
were	O
compared	O
.	O

Results	O
showed	O
distinct	O
cognitive	O
profiles	O
in	O
which	O
FTD	O
patients	O
performed	O
worse	O
than	O
AD	O
patients	O
on	O
the	O
Initiation	O
/	O
Perseveration	O
and	O
Conceptualization	O
subscales	O
while	O
performing	O
better	O
on	O
the	O
Memory	O
and	O
Construction	O
subscales	O
.	O

The	O
distinct	O
subscale	O
profiles	O
correctly	O
classified	O
85	O
%	O
of	O
AD	O
patients	O
and	O
76	O
%	O
of	O
FTD	O
patients	O
.	O

Profiles	O
were	O
maintained	O
in	O
a	O
subset	O
of	O
mildly	O
-	O
to	O
-	O
moderately	O
demented	O
patients	O
(	O
MDRS	O
>	O
or	O
=	O
)	O
and	O
correctly	O
classified	O
89	O
%	O
of	O
these	O
patients	O
.	O

In	O
addition	O
,	O
FTD	O
patients	O
(	O
mean	O
=	O
points	O
/	O
year	O
)	O
declined	O
faster	O
than	O
AD	O
patients	O
(	O
mean	O
=	O
14.8	O
points	O
/	O
year	O
)	O
on	O
MDRS	O
total	O
and	O
specific	O
subscale	O
scores	O
.	O

These	O
results	O
suggest	O
that	O
the	O
MDRS	O
may	O
be	O
a	O
useful	O
adjunct	O
to	O
other	O
clinical	O
measures	O
for	O
distinguishing	O
FTD	O
from	O
AD	O
and	O
tracking	O
the	O
progression	O
of	O
the	O
disorder	O
.	O

Frequency	O
and	O
bases	O
of	O
abnormal	O
performance	O
by	O
healthy	O
adults	O
on	O
neuropsychological	O
testing	O
.	O

The	O
frequency	O
and	O
determinants	O
of	O
abnormal	O
test	O
performance	O
by	O
normal	O
individuals	O
are	O
critically	O
important	O
to	O
clinical	O
inference	O
.	O

Here	O
we	O
compare	O
two	O
approaches	O
to	O
predicting	O
rates	O
of	O
abnormal	O
test	O
performance	O
among	O
healthy	O
individuals	O
with	O
the	O
rates	O
actually	O
shown	O
by	O
327	O
neurologically	O
normal	O
adults	O
aged	O
18	O
-	O
92	O
years	O
.	O

We	O
counted	O
how	O
many	O
participants	O
produced	O
abnormal	O
scores	O
,	O
defined	O
by	O
three	O
different	O
cutoffs	O
with	O
test	O
batteries	O
of	O
varied	O
length	O
,	O
and	O
the	O
number	O
of	O
abnormal	O
scores	O
they	O
produced	O
.	O

Observed	O
rates	O
generally	O
were	O
closer	O
to	O
predictions	O
based	O
on	O
a	O
series	O
of	O
Monte	O
Carlo	O
simulations	O
than	O
on	O
the	O
binomial	O
model	O
.	O

They	O
increased	O
with	O
the	O
number	O
of	O
tests	O
administered	O
,	O
decreased	O
as	O
more	O
stringent	O
cutoffs	O
were	O
used	O
to	O
identify	O
abnormality	O
,	O
varied	O
with	O
the	O
degree	O
of	O
correlation	O
among	O
test	O
scores	O
,	O
and	O
depended	O
on	O
individual	O
differences	O
in	O
age	O
,	O
education	O
,	O
race	O
,	O
sex	O
,	O
and	O
estimated	O
premorbid	O
IQ	O
.	O

Adjusting	O
scores	O
for	O
demographic	O
variables	O
and	O
premorbid	O
IQ	O
did	O
not	O
reduce	O
rates	O
of	O
abnormal	O
performance	O
.	O

However	O
,	O
it	O
eliminated	O
the	O
contribution	O
of	O
these	O
variables	O
to	O
rates	O
of	O
abnormal	O
test	O
performance	O
.	O

These	O
findings	O
raise	O
fundamental	O
questions	O
about	O
the	O
nature	O
and	O
interpretation	O
of	O
abnormal	O
test	O
performance	O
by	O
normal	O
,	O
healthy	O
adults	O
.	O

Neonatal	O
pulmonary	O
tuberculosis	O
evolving	O
to	O
a	O
destroyed	O
lung	O
.	O

Tuberculosis	O
(	O
TB	O
)	O
in	O
the	O
newborn	O
is	O
infrequent	O
,	O
difficult	O
to	O
diagnose	O
and	O
often	O
devastating	O
.	O

Congenital	O
TB	O
is	O
rare	O
,	O
with	O
most	O
neonates	O
and	O
young	O
infants	O
becoming	O
infected	O
after	O
birth	O
.	O

The	O
incidence	O
of	O
neonatal	O
TB	O
might	O
increase	O
in	O
industrialised	O
countries	O
as	O
a	O
result	O
of	O
immigration	O
from	O
countries	O
with	O
higher	O
TB	O
incidence	O
among	O
women	O
of	O
childbearing	O
age	O
.	O

We	O
report	O
two	O
cases	O
of	O
post	O
-	O
natally	O
acquired	O
pulmonary	O
TB	O
in	O
newborns	O
who	O
developed	O
marked	O
lung	O
destruction	O
,	O
a	O
complication	O
of	O
TB	O
which	O
has	O
seldom	O
been	O
described	O
in	O
the	O
first	O
month	O
of	O
life	O
.	O

A	O
high	O
index	O
of	O
clinical	O
suspicion	O
is	O
required	O
when	O
evaluating	O
pregnant	O
women	O
at	O
risk	O
for	O
TB	O
and	O
their	O
ill	O
children	O
,	O
as	O
early	O
identification	O
and	O
treatment	O
can	O
prevent	O
the	O
devastating	O
consequences	O
of	O
TB	O
.	O

Is	O
laparoscopy	O
dying	O
for	O
radical	O
prostatectomy	O
?	O

Training	O
in	O
laparoscopic	O
urology	O
,	O
extensive	O
experimental	O
work	O
,	O
and	O
dedicated	O
surgical	O
performance	O
constitute	O
the	O
foundation	O
of	O
advanced	O
laparoscopic	O
urology	O
,	O
which	O
is	O
currently	O
a	O
reasonable	O
surgical	O
option	O
in	O
pediatrics	O
,	O
reconstructive	O
surgery	O
,	O
and	O
oncology	O
.	O

This	O
article	O
discusses	O
topics	O
related	O
to	O
laparoscopic	O
approaches	O
for	O
radical	O
prostatectomy	O
,	O
focusing	O
on	O
their	O
introduction	O
,	O
development	O
,	O
accomplishments	O
,	O
and	O
current	O
standards	O
and	O
future	O
goals	O
for	O
the	O
minimally	O
invasive	O
treatment	O
of	O
urologic	O
diseases	O
.	O

We	O
highlight	O
the	O
dynamic	O
status	O
of	O
the	O
laparoscopic	O
approach	O
for	O
radical	O
prostatectomy	O
(	O
pure	O
or	O
robotic	O
-	O
assisted	O
)	O
that	O
constitutes	O
one	O
of	O
the	O
most	O
rapidly	O
evolving	O
fields	O
in	O
urology	O
.	O

Mail	O
-	O
in	O
data	O
collection	O
at	O
SPring	O
-	O
8	O
protein	O
crystallography	O
beamlines	O
.	O

A	O
mail	O
-	O
in	O
data	O
collection	O
system	O
makes	O
it	O
possible	O
for	O
beamline	O
users	O
to	O
collect	O
diffraction	O
data	O
without	O
visiting	O
a	O
synchrotron	O
facility	O
.	O

In	O
the	O
mail	O
-	O
in	O
data	O
collection	O
system	O
at	O
SPring	O
-	O
8	O
,	O
users	O
pack	O
crystals	O
into	O
sample	O
trays	O
and	O
send	O
the	O
trays	O
to	O
SPring	O
-	O
8	O
via	O
a	O
courier	O
service	O
as	O
the	O
first	O
step	O
.	O

Next	O
,	O
the	O
user	O
specifies	O
measurement	O
conditions	O
and	O
checks	O
the	O
diffraction	O
images	O
via	O
the	O
Internet	O
.	O

The	O
user	O
can	O
also	O
collect	O
diffraction	O
data	O
using	O
an	O
automated	O
sample	O
changer	O
robot	O
and	O
beamline	O
control	O
software	O
.	O

For	O
distant	O
users	O
there	O
is	O
a	O
newly	O
developed	O
data	O
management	O
system	O
,	O
D	O
-	O
Cha	O
.	O

D	O
-	O
Cha	O
provides	O
a	O
graphical	O
user	O
interface	O
that	O
enables	O
the	O
user	O
to	O
specify	O
the	O
experimental	O
conditions	O
for	O
samples	O
and	O
to	O
check	O
and	O
download	O
the	O
diffraction	O
images	O
using	O
a	O
web	O
browser	O
.	O

This	O
system	O
is	O
now	O
in	O
routine	O
operation	O
and	O
is	O
contributing	O
to	O
high	O
-	O
throughput	O
beamline	O
operation	O
.	O

Direct	O
Comparison	O
between	O
ICSI	O
-	O
Mediated	O
DNA	O
Transfer	O
and	O
Pronuclear	O
DNA	O
Microinjection	O
for	O
Producing	O
Transgenic	O
Rats	O
.	O

Production	O
efficiency	O
of	O
transgenic	O
rats	O
was	O
compared	O
directly	O
between	O
the	O
routine	O
pronuclear	O
microinjection	O
of	O
exogenous	O
DNA	O
solution	O
(	O
PNMI	O
-	O
Tg	O
method	O
)	O
and	O
the	O
ooplasmic	O
injection	O
of	O
sperm	O
cells	O
exposed	O
to	O
exogenous	O
DNA	O
solution	O
(	O
ICSI	O
-	O
Tg	O
method	O
)	O
using	O
six	O
DNA	O
constructs	O
.	O

The	O
overall	O
production	O
efficiency	O
per	O
treated	O
oocyte	O
in	O
the	O
ICSI	O
-	O
Tg	O
method	O
(	O
mean	O
1.1	O
%	O
,	O
range	O
0.2	O
to	O
3.1	O
%	O
)	O
was	O
similar	O
to	O
that	O
in	O
the	O
PNMI	O
-	O
Tg	O
method	O
(	O
mean	O
1.1	O
%	O
,	O
range	O
0	O
to	O
2.4	O
%	O
)	O
.	O

An	O
advantage	O
of	O
the	O
ICSI	O
-	O
Tg	O
method	O
in	O
the	O
production	O
of	O
transgenic	O
rats	O
is	O
noted	O
in	O
cases	O
in	O
which	O
a	O
low	O
yield	O
of	O
pronuclear	O
zygotes	O
is	O
an	O
inevitable	O
fate	O
of	O
the	O
rat	O
strain	O
.	O

Some	O
novel	O
6	B
-	I
fluoro	I
-	I
7	I
-	I
substituted	I
-	I
1,4	I
-	I
dihydro	I
-	I
4	I
-	I
oxoquinoline	I
-	I
3	I
-	I
carboxylic	I
acids	I
have	O
been	O
prepared	O
.	O

At	O
the	O
N	O
-	O
1	O
position	O
""""	O
standard	O
""""	O
substitution	O
was	O
employed	O
with	O
the	O
ethyl	B
,	O
cyclopropyl	B
,	O
and	O
p	B
-	I
fluorophenyl	I
groups	B
being	O
used	O
.	O

At	O
C	O
-	O
7	O
the	O
introduction	O
of	O
some	O
novel	O
piperazines	B
was	O
made	O
.	O

Most	O
notably	O
,	O
2	B
-	I
(	I
fluoromethyl	I
)	I
piperazine	I
(	O
)	O
and	O
hexahydro	B
-	I
6	I
-	I
fluoro	I
-	I
1H	I
-	I
1,4	I
-	I
diazepine	I
(	O
16	O
,	O
fluorohomopiperazine	B
)	O
at	O
the	O
quinolone	B
C	O
-	O
7	O
position	O
produced	O
products	O
with	O
similar	O
in	O
vitro	O
antibacterial	O
activity	O
as	O
the	O
ciprofloxacin	B
reference	O
.	O

The	O
in	O
vivo	O
efficacy	O
of	O
1	B
-	I
cyclopropyl	I
-	I
6	I
-	I
fluoro	I
-	I
7	I
-	I
[	I
3	I
-	I
(	I
fluoromethyl	I
)	I
piperazinyl	I
]	I
-	I
1,4	I
-	I
dihydro	I
-	I
4	I
-	I
oxoquinoline	I
-	I
3	I
-	I
carboxylic	I
acid	I
(	O
)	O
was	O
excellent	O
with	O
better	O
oral	O
absorption	O
than	O
ciprofloxacin	B
(	O
2	O
)	O
.	O

There	O
is	O
reported	O
the	O
first	O
four	O
members	O
of	O
heteroarotinoids	B
,	O
the	O
names	O
of	O
which	O
are	O
ethyl	B
(	I
E	I
)	I
-	I
p	I
-	I
[	I
2	I
-	I
(	I
4,4	I
-	I
dimethylthiochroman	I
-	I
6	I
-	I
yl	I
)	I
propenyl	I
]	I
benzoate	I
(	O
1b	O
)	O
,	O
ethyl	B
(	I
E	I
)	I
-	I
p	I
-	I
[	I
2	I
-	I
(	I
4,4	I
-	I
dimethylchroman	I
-	I
6	I
-	I
yl	I
)	I
propenyl	I
]	I
benzoate	I
(	O
1c	O
)	O
,	O
ethyl	B
(	I
E	I
)	I
-	I
p	I
-	I
[	I
2	I
-	I
(	I
4,4	I
-	I
dimethyl	I
-	I
1	I
-	I
oxothiochroman	I
-	I
6	I
-	I
yl	I
)	I
propenyl	I
]	I
benzoate	I
(	O
1d	O
)	O
,	O
and	O
(	B
E	I
)	I
-	I
p	I
-	I
[	I
2	I
-	I
(	I
4,4	I
-	I
dimethylchroman	I
-	I
6	I
-	I
yl	I
)	I
propenyl	I
]	I
benzoic	I
acid	I
(	O
1e	O
)	O
.	O

IR	O
,	O
1H	O
NMR	O
and	O
13C	O
NMR	O
data	O
have	O
been	O
recorded	O
for	O
each	O
compound	O
and	O
support	O
the	O
structural	O
assignments	O
.	O

To	O
provide	O
a	O
firm	O
basis	O
for	O
comparison	O
purposes	O
of	O
future	O
analogues	O
,	O
an	O
X	O
-	O
ray	O
analysis	O
was	O
performed	O
on	O
a	O
single	O
crystal	O
of	O
ethyl	B
(	I
E	I
)	I
-	I
p	I
-	I
[	I
2	I
-	I
(	I
4,4	I
-	I
dimethylthiochroman	I
-	I
6	I
-	I
yl	I
)	I
propenyl	I
]	I
benzoate	I
(	O
1b	O
)	O
and	O
a	O
precursor	O
4,4	B
-	I
dimethylthiochroman	I
-	I
6	I
-	I
yl	I
methyl	I
ketone	I
1,1	I
-	I
dioxide	I
(	O
18	O
)	O
.	O

These	O
data	O
for	O
the	O
heteroarotinoid	B
1b	O
revealed	O
that	O
the	O
two	O
aryl	O
ring	O
systems	O
were	O
nearly	O
perpendicular	O
in	O
each	O
of	O
the	O
two	O
molecules	O
present	O
in	O
the	O
unit	O
cell	O
(	O
86.37	O
degrees	O
and	O
84.17	O
degrees	O
,	O
respectively	O
)	O
.	O

The	O
space	O
group	O
for	O
both	O
molecules	O
was	O
P1	O
in	O
triclinic	O
systems	O
.	O

Unit	O
cell	O
dimensions	O
(	O
at	O
15	O
degrees	O
C	O
)	O
are	O
as	O
follows	O
:	O
for	O
1b	O
,	O
a	O
=	O
(	O
6	O
)	O
A	O
,	O
b	O
=	O
14.760	O
(	O
3	O
)	O
A	O
,	O
c	O
=	O
7.679	O
(	O
2	O
)	O
A	O
,	O
alpha	O
=	O
113.33	O
(	O
2	O
)	O
degrees	O
,	O
beta	O
=	O
79.45	O
(	O
2	O
)	O
degrees	O
,	O
gamma	O
=	O
79.98	O
(	O
2	O
)	O
degrees	O
,	O
Z	O
=	O
4	O
;	O
for	O
18	O
,	O
a	O
=	O
9.292	O
(	O
5	O
)	O
A	O
,	O
b	O
=	O
9.291	O
(	O
5	O
)	O
A	O
,	O
c	O
=	O
7.951	O
(	O
3	O
)	O
A	O
,	O
alpha	O
=	O
(	O
3	O
)	O
degrees	O
,	O
beta	O
=	O
77.49	O
(	O
3	O
)	O
degrees	O
,	O
gamma	O
=	O
79.60	O
(	O
4	O
)	O
degrees	O
,	O
Z	O
=	O
2	O
.	O

The	O
sulfur	B
-	O
containing	O
ring	O
is	O
in	O
a	O
distorted	O
half	O
-	O
chair	O
in	O
1b	O
and	O
the	O
methyl	B
carbon	B
C	O
(	O
12	O
)	O
is	O
shown	O
to	O
be	O
trans	O
to	O
H	O
(	O
13	O
)	O
at	O
the	O
C	O
(	O
11	O
)	O
-	O
C	O
(	O
13	O
)	O
bond	O
.	O

The	O
biological	O
activity	O
of	O
these	O
arotinoids	B
was	O
determined	O
in	O
the	O
tracheal	O
organ	O
culture	O
assay	O
and	O
compared	O
with	O
trans	B
-	I
retinoic	I
acid	I
for	O
ability	O
to	O
reverse	O
keratinization	O
in	O
vitamin	B
A	I
deficient	O
hamsters	O
.	O

The	O
ester	O
1b	O
displayed	O
activity	O
about	O
one	O
-	O
half	O
log	O
unit	O
less	O
than	O
that	O
of	O
the	O
reference	O
while	O
1c	O
and	O
1e	O
had	O
activity	O
nearly	O
one	O
log	O
until	O
less	O
than	O
trans	B
-	I
retinoic	I
acid	I
.	O

The	O
sulfoxide	B
was	O
the	O
least	O
active	O
of	O
the	O
heteroretinoids	B
.	O

The	O
isomeric	O
4	B
-	I
(	I
3	I
-	I
chloro	I
-	I
4	I
-	I
hydroxyphenyl	I
)	I
-	I
and	O
4	B
-	I
(	I
4	I
-	I
chloro	I
-	I
3	I
-	I
hydroxyphenyl	I
)	I
-	I
1,2,3,4	I
-	I
tetrahydroisoquinolines	I
,	O
the	O
N	B
-	I
methyl	I
derivative	B
of	O
the	O
4	B
-	I
(	I
4	I
-	I
chloro	I
-	I
3	I
-	I
hydroxyphenyl	I
)	I
isomer	B
,	O
and	O
4	B
-	I
(	I
3	I
-	I
hydroxyphenyl	I
)	I
-	I
1,2,3,4	I
-	I
tetrahydroisoquinoline	I
were	O
synthesized	O
and	O
evaluated	O
for	O
dopamine	O
D	O
-	O
1	O
antagonist	O
activity	O
.	O

The	O
4	B
-	I
(	I
3	I
-	I
chloro	I
-	I
4	I
-	I
hydroxyphenyl	I
)	I
and	O
the	O
4	B
-	I
(	I
3	I
-	I
hydroxyphenyl	I
)	I
isomer	B
possessed	O
similar	O
potencies	O
as	O
D	O
-	O
1	O
antagonists	O
.	O

Introduction	O
of	O
the	O
N	B
-	I
methyl	I
group	B
enhanced	O
potency	O
about	O
twofold	O
.	O

The	O
""""	O
pharmacophore	O
""""	O
for	O
selective	O
dopamine	O
D	O
-	O
1	O
antagonist	O
activity	O
appears	O
to	O
be	O
a	O
tertiary	O
2	B
-	I
(	I
3	I
-	I
hydroxyphenyl	I
)	I
-	I
2	I
-	I
phenethylamine	I
.	O

The	O
syntheses	O
of	O
(	B
3RS	I
,	I
4RS	I
)	I
-	I
4	I
-	I
hydroxypiperidine	I
-	I
3	I
-	I
carboxylic	I
acid	I
(	O
4	O
)	O
,	O
(	B
3RS	I
,	I
5SR	I
)	I
-	I
5	I
-	I
hydroxypiperidine	I
-	I
3	I
-	I
carboxylic	I
acid	I
(	O
)	O
,	O
(	B
3RS	I
,	I
4SR	I
)	I
-	I
4	I
-	I
acetamidopiperidine	I
-	I
3	I
-	I
carboxylic	I
acid	I
(	O
)	O
,	O
and	O
(	B
3RS	I
,	I
5SR	I
)	I
-	I
5	I
-	I
acetamidopiperidine	I
-	I
3	I
-	I
carboxylic	I
acid	I
(	O
18	O
)	O
,	O
related	O
to	O
the	O
specific	O
gamma	B
-	I
aminobutyric	I
acid	I
(	O
GABA	B
)	O
uptake	O
inhibitors	O
(	B
RS	I
)	I
-	I
piperidine	I
-	I
3	I
-	I
carboxylic	I
acid	I
(	O
nipecotic	B
acid	I
)	O
and	O
(	B
3RS	I
,	I
4SR	I
)	I
-	I
4	I
-	I
hydroxypiperidine	I
-	I
3	I
-	I
carboxylic	I
acid	I
(	O
21	O
)	O
,	O
are	O
described	O
.	O

Furthermore	O
,	O
(	B
3RS	I
,	I
4SR	I
)	I
-	I
3	I
-	I
hydroxypiperidine	I
-	I
4	I
-	I
carboxylic	I
acid	I
(	O
14	O
)	O
,	O
related	O
to	O
the	O
specific	O
GABA	B
agonist	O
piperidine	B
-	I
4	I
-	I
carboxylic	I
acid	I
(	O
isonipecotic	B
acid	I
)	O
,	O
has	O
been	O
synthesized	O
.	O

The	O
structures	O
of	O
4	O
,	O
,	O
14	O
,	O
18	O
,	O
and	O
have	O
been	O
established	O
by	O
-	O
MHz	O
1H	O
NMR	O
spectroscopic	O
analyses	O
.	O

The	O
affinity	O
of	O
the	O
compounds	O
for	O
the	O
GABA	O
receptors	O
and	O
for	O
the	O
neuronal	O
(	O
synaptosomal	O
)	O
GABA	B
uptake	O
system	O
in	O
vitro	O
has	O
been	O
measured	O
.	O

Compound	O
14	O
interacts	O
selectively	O
with	O
the	O
GABA	O
receptors	O
but	O
less	O
effectively	O
than	O
isonipecotic	B
acid	I
and	O
the	O
cis	O
-	O
isomer	O
22	O
.	O

Compounds	O
4	O
,	O
18	O
,	O
and	O
are	O
inhibitors	O
of	O
the	O
GABA	B
uptake	O
system	O
,	O
although	O
much	O
weaker	O
than	O
nipecotic	B
acid	I
and	O
(	B
3RS	I
,	I
4SR	I
)	I
-	I
4	I
-	I
hydroxypiperidine	I
-	I
3	I
-	I
carboxylic	I
acid	I
(	O
21	O
)	O
.	O

Compound	O
is	O
inactive	O
in	O
both	O
test	O
systems	O
.	O

Differential	O
effects	O
of	O
luteinizing	O
hormone	O
-	O
releasing	O
hormone	O
on	O
follicle	O
-	O
stimulating	O
hormone	O
-	O
dependent	O
responses	O
in	O
rat	O
granulosa	O
cells	O
and	O
Sertoli	O
cells	O
in	O
vitro	O
.	O

The	O
abilities	O
of	O
LHRH	O
and	O
a	O
potent	O
LHRH	O
agonist	O
(	O
[	O
D	O
-	O
Ser	O
-	O
(	O
But	O
)	O
,	O
6	O
,	O
des	O
-	O
Gly	O
-	O
NH210	O
]	O
LHRH	O
ethylamide	O
)	O
inhibit	O
FSH	O
responses	O
by	O
rat	O
granulosa	O
cells	O
and	O
Sertoli	O
cells	O
in	O
vitro	O
have	O
been	O
compared	O
.	O

Granulosa	O
cells	O
isolated	O
from	O
22	O
-	O
or	O
25	O
-	O
day	O
-	O
old	O
diethylstilbestrol	B
-	O
primed	O
rats	O
and	O
cultured	O
under	O
defined	O
conditions	O
for	O
48	O
h	O
with	O
NIH	B
-	I
FSH	I
-	I
S13	I
(	O
ng	O
/	O
ml	O
)	O
or	O
cholera	B
toxin	I
(	O
0.1	O
microgram	O
/	O
ml	O
)	O
showed	O
increased	O
aromatase	O
activity	O
,	O
as	O
determined	O
by	O
the	O
release	O
of	O
3H2O	O
from	O
[	B
1	I
beta	I
-	I
3H	I
]	I
testosterone	I
.	O

LHRH	O
(	O
(	O
-	O
7	O
)	O
M	O
)	O
or	O
th	O
agonist	O
(	O
(	O
-	O
8	O
)	O
M	O
)	O
added	O
simultaneously	O
with	O
FSH	O
or	O
cholera	B
toxin	I
inhibited	O
the	O
effects	O
on	O
the	O
release	O
of	O
3H2O	B
without	O
influencing	O
the	O
protein	O
content	O
of	O
the	O
cell	O
cultures	O
.	O

A	O
smaller	O
stimulation	O
of	O
3H2O	B
production	O
occurred	O
with	O
(	B
Bu	I
)	I
2cAMP	I
(	O
1.0	O
mM	O
)	O
plus	O
3	B
-	I
isobutyl	I
-	I
l	I
-	I
methylxanthine	I
(	O
0.1	O
mM	O
)	O
,	O
and	O
this	O
was	O
partially	O
suppressed	O
in	O
the	O
presence	O
of	O
LHRH	O
or	O
the	O
agonist	O
.	O

Parallel	O
studies	O
with	O
Sertoli	O
cells	O
from	O
15	O
-	O
or	O
-	O
day	O
-	O
old	O
rats	O
demonstrated	O
that	O
culture	O
under	O
appropriate	O
conditions	O
with	O
FSH	O
,	O
cholera	B
toxin	I
,	O
or	O
(	B
Bu	I
)	I
2cAMP	I
(	O
0.5	O
mM	O
)	O
for	O
24	O
h	O
caused	O
an	O
increase	O
in	O
cellular	O
aromatase	O
activity	O
and	O
enhanced	O
secretion	O
into	O
the	O
medium	O
of	O
plasminogen	O
activator	O
.	O

However	O
,	O
no	O
inhibition	O
by	O
LHRH	O
(	O
(	O
-	O
7	O
)	O
or	O
(	O
-	O
9	O
)	O
M	O
)	O
or	O
the	O
agonist	O
(	O
(	O
-	O
6	O
)	O
or	O
(	O
-	O
8	O
)	O
M	O
)	O
occurred	O
when	O
the	O
peptides	O
were	O
added	O
either	O
simultaneously	O
or	O
24	O
h	O
before	O
the	O
stimulatory	O
agent	O
.	O

Similarly	O
,	O
Sertoli	O
cells	O
from	O
11	O
-	O
day	O
-	O
old	O
rats	O
treated	O
daily	O
with	O
LHRH	O
agonist	O
for	O
5	O
days	O
in	O
culture	O
,	O
showed	O
no	O
inhibition	O
of	O
aromatase	O
activity	O
after	O
a	O
4	O
-	O
h	O
stimulation	O
with	O
FSH	O
or	O
(	B
Bu	I
)	I
2cAMP	I
.	O

FSH	O
dose	O
-	O
response	O
curves	O
(	O
0	O
-	O
300	O
ng	O
/	O
ml	O
)	O
for	O
aromatase	O
activity	O
were	O
shown	O
to	O
be	O
similar	O
after	O
5	O
days	O
of	O
culture	O
with	O
or	O
without	O
(	O
-	O
8	O
)	O
M	O
LHRH	O
agonist	O
,	O
indicating	O
that	O
the	O
LHRH	O
did	O
not	O
cause	O
a	O
shift	O
in	O
the	O
sensitivity	O
to	O
FSH	O
.	O

The	O
lack	O
of	O
inhibition	O
was	O
seen	O
in	O
Sertoli	O
cell	O
cultures	O
maintained	O
at	O
37	O
or	O
32	O
C	O
.	O

The	O
enzyme	O
digestion	O
method	O
used	O
to	O
isolated	O
Sertoli	O
cells	O
was	O
not	O
responsible	O
for	O
the	O
lack	O
of	O
effects	O
of	O
LHRH	O
,	O
since	O
cell	O
cultures	O
prepared	O
without	O
the	O
aid	O
of	O
proteolytic	O
enzymes	O
showed	O
similar	O
FSH	O
stimulation	O
of	O
aromatase	O
activity	O
in	O
the	O
presence	O
or	O
absence	O
of	O
(	O
-	O
8	O
)	O
M	O
agonist	O
.	O

Further	O
,	O
there	O
was	O
no	O
evidence	O
of	O
degradation	O
of	O
the	O
LHRH	O
agonist	O
when	O
incubated	O
with	O
Sertoli	O
cell	O
cultures	O
.	O

From	O
these	O
studies	O
,	O
we	O
conclude	O
that	O
1	O
)	O
granulosa	O
cells	O
and	O
Sertoli	O
cells	O
from	O
immature	O
rats	O
differ	O
in	O
their	O
responses	O
to	O
LHRH	O
,	O
and	O
2	O
)	O
the	O
immature	O
Sertoli	O
cell	O
is	O
an	O
unlikely	O
target	O
for	O
a	O
direct	O
inhibiting	O
influence	O
of	O
LHRH	O
on	O
spermatogenesis	O
.	O

Condensation	O
of	O
14	B
-	I
bromodaunorubicin	I
with	O
thiols	B
in	O
methanol	B
,	O
in	O
the	O
presence	O
of	O
potassium	B
carbonate	I
,	O
resulted	O
in	O
the	O
formation	O
of	O
14	B
-	I
thia	I
analogues	B
of	O
the	O
antitumor	O
antibiotic	O
adriamycin	B
.	O

However	O
,	O
similar	O
condensation	O
of	O
N	B
-	I
(	I
trifluoroacetyl	I
)	I
-	I
14	I
-	I
iododaunorubicin	I
with	O
thiols	O
invariably	O
led	O
to	O
a	O
redox	O
reaction	O
,	O
with	O
the	O
formation	O
of	O
N	B
-	I
(	I
trifluoroacetyl	I
)	I
daunorubicin	I
and	O
disulfides	B
.	O

Accordingly	O
,	O
N	B
-	I
(	I
trifluoroacetyl	I
)	I
-	I
14	I
-	I
bromodaunorubicin	I
was	O
used	O
for	O
reaction	O
with	O
thiols	B
to	O
yield	O
thia	O
analogues	O
of	O
the	O
clinically	O
active	O
but	O
non	O
-	O
DNA	O
-	O
binding	O
adriamycin	B
analogue	B
N	B
-	I
(	I
trifluoroacetyl	I
)	I
adriamycin	I
14	I
-	I
valerate	I
(	O
AD	O
32	O
)	O
.	O

Reaction	O
of	O
14	B
-	I
bromoadunorubicin	I
with	O
alpha	B
,	I
omega	I
-	I
alkanedithiols	I
gave	O
bis	B
(	I
thiaadriamycin	I
)	I
analogues	B
as	O
potential	O
difunctional	O
intercalating	O
agents	O
.	O

The	O
aforementioned	O
products	O
,	O
plus	O
two	O
related	O
phenylselena	B
derivatives	B
,	O
were	O
examined	O
for	O
in	O
vitro	O
growth	O
inhibition	O
,	O
in	O
vivo	O
antitumor	O
activity	O
,	O
and	O
,	O
where	O
appropriate	O
,	O
DNA	O
binding	O
.	O

A	O
number	O
of	O
agents	O
,	O
most	O
notably	O
14	B
-	I
(	I
carbethoxymethyl	I
)	I
-	I
14	I
-	I
thiaadriamycin	I
and	O
N	B
-	I
(	I
trifluoroacetyl	I
)	I
-	I
14	I
-	I
phenyl	I
-	I
14	I
-	I
selenaadriamycin	I
,	O
were	O
active	O
against	O
murine	O
L1210	O
leukemia	O
in	O
vivo	O
.	O

Several	O
of	O
the	O
amino	B
glycoside	I
unsubstituted	I
14	I
-	I
thiaadriamycin	I
analogues	B
exhibited	O
DNA	O
-	O
binding	O
properties	O
equivalent	O
to	O
those	O
of	O
adriamycin	B
.	O

Spiro	O
[	O
isobenzofuran	O
-	O
1	O
(	O
3H	O
)	O
,	O
4	O
'	O
-	O
piperidines	O
]	O
and	O
the	O
corresponding	O
benzofuran	B
and	O
benzopyran	B
derivatives	B
have	O
been	O
synthesized	O
and	O
evaluated	O
as	O
sigma	O
ligands	O
.	O

The	O
compounds	O
are	O
related	O
to	O
Lu	B
28	I
-	I
179	I
(	O
1	B
'	I
-	I
[	I
4	I
-	I
[	I
1	I
-	I
(	I
4	I
-	I
fluorophenyl	I
)	I
-	I
1H	I
-	I
indol	I
-	I
3	I
-	I
yl	I
]	I
-	I
1	I
-	I
butyl	I
]	I
spiro	I
[	I
isobenzofuran	I
-	I
1	I
(	I
3H	I
)	I
,	I
4	I
'	I
-	I
piperidine	I
]	I
)	O
that	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
selective	O
sigma	O
2	O
ligand	O
with	O
affinity	O
in	O
the	O
subnanomolar	O
range	O
.	O

The	O
object	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
structural	O
factors	O
governing	O
sigma	O
1	O
/	O
sigma	O
2	O
affinity	O
and	O
selectivity	O
within	O
this	O
class	O
of	O
compounds	O
.	O

The	O
N	B
-	I
substituent	I
in	O
spiro	B
[	I
isobenzofuran	I
-	I
1	I
(	I
3H	I
)	I
,	I
4	I
'	I
-	I
piperidines	I
]	I
is	O
highly	O
important	O
,	O
both	O
for	O
affinity	O
and	O
selectivity	O
.	O

Spiropiperidines	B
with	O
no	O
or	O
small	O
N	B
-	I
substituents	I
(	O
H	B
,	O
Me	B
,	O
Et	B
)	O
exert	O
very	O
low	O
affinity	O
for	O
both	O
sigma	O
1	O
and	O
sigma	O
2	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
,	O
sigma	O
2	O
)	O
&	O
gt	O
;	O
nM	O
)	O
,	O
whereas	O
medium	O
-	O
sized	O
substituents	O
(	O
e.g.	O
,	O
Pr	B
,	O
Bu	B
,	O
Ph	B
(	I
CH2	I
)	I
2	I
)	O
result	O
in	O
potent	O
,	O
but	O
unselective	O
compounds	O
(	O
IC50	O
(	O
sigma	O
1	O
,	O
sigma	O
2	O
)	O
=	O
2	O
-	O
5	O
nM	O
)	O
.	O

Increasing	O
the	O
chain	O
length	O
and	O
the	O
lipophilicity	O
of	O
the	O
N	B
-	I
substituent	I
result	O
in	O
compounds	O
in	O
which	O
high	O
affinity	O
for	O
sigma	O
2	O
binding	O
sites	O
is	O
retained	O
and	O
with	O
selectivity	O
for	O
sigma	O
2	O
vs	O
sigma	O
1	O
binding	O
sites	O
(	O
e.g.	O
,	O
4	B
-	I
cyclohexyl	I
-	I
1	I
-	I
butyl	I
:	O
IC50	O
-	O
(	O
sigma	O
1	O
)	O
=	O
1.5	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.07	O
nM	O
)	O
.	O

Introduction	O
of	O
substituents	O
in	O
the	O
benzene	B
ring	O
of	O
the	O
spiro	B
[	I
isobenzofuran	I
-	I
1	I
(	I
3H	I
)	I
,	I
4	I
'	I
-	I
piperidine	I
]	I
ring	O
system	O
of	O
Lu	B
28	I
-	I
179	I
mainly	O
affects	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
.	O

Compounds	O
with	O
substituents	O
(	O
F	B
,	O
CF3	B
)	O
in	O
the	O
4	O
-	O
or	O
7	O
-	O
position	O
of	O
the	O
isobenzofuran	B
display	O
high	O
affinity	O
for	O
sigma	O
2	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.5	O
-	O
2	O
nM	O
)	O
and	O
very	O
low	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
)	O
&	O
gt	O
;	O
nM	O
)	O
.	O

Compounds	O
with	O
substituents	O
(	O
F	B
,	O
CF3	B
,	O
Me	B
)	O
in	O
the	O
5	O
-	O
or	O
6	O
-	O
position	O
of	O
the	O
isobenzofuran	B
exert	O
increased	O
affinity	O
for	O
sigma	O
1	O
binding	O
sites	O
(	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
5	O
-	O
30	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.3	O
-	O
7	O
nM	O
)	O
,	O
thus	O
rendering	O
unselective	O
compounds	O
.	O

Exchanging	O
the	O
isobenzofuran	B
moiety	O
of	O
Lu	B
28	I
-	I
179	I
with	O
thioisobenzofuran	B
,	O
benzofuran	B
,	O
or	O
benzopyran	B
also	O
has	O
a	O
pronounced	O
effect	O
on	O
both	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
binding	O
sites	O
.	O

The	O
position	O
of	O
the	O
oxygen	O
atom	O
and	O
the	O
position	O
of	O
the	O
spiroconnection	O
with	O
the	O
4	O
-	O
position	O
of	O
the	O
piperidine	B
ring	O
were	O
varied	O
,	O
and	O
only	O
compounds	O
in	O
which	O
both	O
the	O
benzene	B
ring	O
and	O
the	O
heteroatom	O
are	O
attached	O
directly	O
to	O
the	O
piperidine	B
ring	O
retain	O
high	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
2	O
binding	O
sites	O
(	O
e.g.	O
,	O
3,4	B
-	I
dihydro	I
-	I
1	I
'	I
-	I
[	I
4	I
-	I
[	I
1	I
-	I
(	I
4	I
-	I
fluorophenyl	I
)	I
-	I
1H	I
-	I
indol	I
-	I
3	I
-	I
yl	I
]	I
-	I
1	I
-	I
butyl	I
]	I
spiro	I
[	I
1H	I
-	I
2	I
-	I
benzopyran	I
-	I
1,4	I
'	I
-	I
piperidine	I
]	I
:	O
IC50	O
(	O
sigma	O
1	O
)	O
=	O
53	O
nM	O
,	O
IC50	O
(	O
sigma	O
2	O
)	O
=	O
0.9	O
nM	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
WORDS	O
)	O

In	O
order	O
to	O
develop	O
tracers	O
with	O
higher	O
specific	O
activity	O
to	O
supplant	O
the	O
currently	O
used	O
[	B
3H	I
]	I
-	I
8	I
-	I
OH	I
-	I
DPAT	I
[	O
8	B
-	I
hydroxy	I
-	I
2	I
-	I
(	I
N	I
,	I
N	I
-	I
di	I
-	I
n	I
-	I
propylamino	I
)	I
tetralin	I
]	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
5	O
-	O
HT1A	O
receptors	O
,	O
a	O
new	O
radioiodinated	O
ligand	O
was	O
prepared	O
.	O

(	B
R	I
,	I
S	I
)	I
-	I
trans	I
-	I
8	I
-	I
Hydroxy	I
-	I
2	I
-	I
[	I
N	I
-	I
n	I
-	I
propyl	I
-	I
N	I
-	I
(	I
3	I
'	I
-	I
iodo	I
-	I
2	I
'	I
-	I
propenyl	I
)	I
amino	I
]	I
tetralin	I
(	O
trans	B
-	I
8	I
-	I
OH	I
-	I
PIPAT	I
)	O
,	O
8	O
,	O
was	O
synthesized	O
by	O
a	O
-	O
step	O
reaction	O
.	O

Binding	O
studies	O
with	O
rat	O
hippocampal	O
membrane	O
homogenates	O
showed	O
that	O
8	O
exhibited	O
a	O
Ki	O
value	O
of	O
0.92	O
nM	O
against	O
(	B
R	I
,	I
S	I
)	I
-	I
[	I
3H	I
]	I
-	I
8	I
-	I
OH	I
-	I
DPAT	I
.	O

Radiolabeled	O
[	B
125I	I
]	I
-	I
8	O
was	O
prepared	O
from	O
the	O
corresponding	O
tri	B
-	I
n	I
-	I
butyltin	I
precursor	O
via	O
an	O
oxidative	O
iododestannylation	O
reaction	O
with	O
sodium	O
[	B
125I	I
]	I
iodide	I
.	O

Binding	O
studies	O
in	O
the	O
hippocampal	O
homogenates	O
revealed	O
that	O
[	B
125I	I
]	I
-	I
8	O
bound	O
to	O
a	O
single	O
high	O
-	O
affinity	O
site	O
(	O
Kd	O
=	O
0.38	O
+	O
/	O
-	O
0.03	O
nM	O
,	O
Bmax	O
=	O
+	O
/	O
-	O
fmol	O
/	O
mg	O
of	O
protein	O
)	O
.	O

Competition	O
binding	O
experiments	O
clearly	O
indicated	O
that	O
the	O
new	O
ligand	O
displayed	O
the	O
expected	O
5	O
-	O
HT1A	O
receptor	O
binding	O
profile	O
.	O

The	O
rank	O
order	O
of	O
potency	O
was	O
(	B
R	I
,	I
S	I
)	I
-	I
trans	I
-	I
8	I
-	I
OH	I
-	I
PIPAT	I
&	O
gt	O
;	O
(	B
R	I
,	I
S	I
)	I
-	I
8	I
-	I
OH	I
-	I
DPAT	I
&	O
gt	O
;	O
WB4101	B
&	O
gt	O
;	O
5	O
-	O
HT	O
&	O
gt	O
;	O
(	B
R	I
,	I
S	I
)	I
-	I
trans	I
-	I
7	I
-	I
OH	I
-	I
PIPAT	I
&	O
gt	O
;	O
(	B
R	I
,	I
S	I
)	I
-	I
7	I
-	I
OH	I
-	I
DPAT	I
&	O
gt	O
;	O
(	B
R	I
,	I
S	I
)	I
-	I
propranolol	I
&	O
gt	O
;	O
spiperone	B
&	O
gt	O
;	O
&	O
gt	O
;	O
ketanserin	B
&	O
gt	O
;	O
&	O
gt	O
;	O
dopamine	B
&	O
gt	O
;	O
atropine	B
.	O

This	O
new	O
ligand	O
offers	O
several	O
unique	O
advantages	O
,	O
including	O
high	O
specific	O
activity	O
,	O
high	O
binding	O
affinity	O
,	O
and	O
low	O
nonspecific	O
binding	O
,	O
all	O
of	O
which	O
make	O
it	O
an	O
excellent	O
probe	O
for	O
the	O
investigation	O
and	O
characterization	O
of	O
5	O
-	O
HT1A	O
receptors	O
.	O

The	O
regulation	O
of	O
total	O
creatine	B
content	O
in	O
a	O
myoblast	O
cell	O
line	O
.	O

Total	O
cellular	O
creatine	B
content	O
is	O
an	O
important	O
bioenergetic	O
parameter	O
in	O
skeletal	O
muscle	O
.	O

To	O
understand	O
its	O
regulation	O
we	O
investigated	O
creatine	B
transport	O
and	O
accumulation	O
in	O
the	O
G8	O
cultured	O
skeletal	O
myoblast	O
line	O
.	O

Like	O
other	O
cell	O
types	O
,	O
these	O
contain	O
a	O
creatine	O
transporter	O
,	O
whose	O
activity	O
,	O
measured	O
using	O
a	O
radiolabelling	O
technique	O
,	O
was	O
saturable	O
(	O
Km	O
=	O
+	O
/	O
-	O
25	O
microM	O
)	O
and	O
largely	O
dependent	O
on	O
extracellular	O
[	O
Na+	O
]	O
.	O

To	O
study	O
sustained	O
influences	O
on	O
steady	O
state	O
creatine	B
concentration	O
we	O
measured	O
total	O
cellular	O
creatine	B
content	O
using	O
a	O
fluorimetric	O
method	O
in	O
48	O
h	O
incubations	O
.	O

We	O
found	O
that	O
the	O
total	O
cellular	O
creatine	B
content	O
was	O
relatively	O
independent	O
of	O
extracellular	O
creatine	B
concentration	O
,	O
consistent	O
with	O
high	O
affinity	O
sodium	B
-	O
dependent	O
uptake	O
balanced	O
by	O
slow	O
passive	O
efflux	O
.	O

Accordingly	O
,	O
in	O
creatine	B
-	O
free	O
incubations	O
net	O
creatine	B
efflux	O
was	O
slow	O
(	O
5	O
+	O
/	O
-	O
1	O
%	O
of	O
basal	O
creatine	B
content	O
per	O
day	O
over	O
6	O
days	O
)	O
,	O
while	O
creatine	B
content	O
in	O
48	O
h	O
incubations	O
was	O
reduced	O
by	O
28	O
+	O
/	O
-	O
13	O
%	O
of	O
control	O
by	O
the	O
Na+	O
,	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
inhibitor	O
ouabain	B
.	O

Creatine	B
accumulation	O
after	O
48	O
h	O
was	O
stimulated	O
by	O
treatment	O
with	O
the	O
mixed	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
agonist	O
noradrenaline	B
,	O
the	O
beta	O
-	O
adrenergic	O
agonist	O
isoproterenol	B
,	O
the	O
beta	O
2	O
-	O
agonist	O
clenbuterol	B
and	O
the	O
cAMP	B
analogue	B
N6	B
,	I
2	I
'	I
-	I
O	I
-	I
dibutyryladenosine	I
3	I
'	I
,	I
5	I
'	I
-	I
cyclic	I
monophosphate	I
,	O
but	O
was	O
unaffected	O
by	O
the	O
alpha	O
1	O
adrenergic	O
agonist	O
methoxamine	B
.	O

The	O
noradrenaline	B
enhancement	O
of	O
creatine	B
accumulation	O
at	O
48	O
h	O
was	O
inhibited	O
by	O
the	O
mixed	O
alpha	O
-	O
and	O
beta	O
-	O
antagonist	O
labetalol	B
and	O
by	O
the	O
beta	O
-	O
antagonist	O
propranolol	B
,	O
but	O
was	O
unaffected	O
by	O
the	O
alpha	O
2	O
antagonist	O
phentolamine	B
;	O
greater	O
inhibition	O
was	O
caused	O
by	O
the	O
beta	O
2	O
antagonist	O
butoxamine	B
than	O
the	O
beta	O
1	O
antagonist	O
atenolol	B
.	O

Creatine	B
accumulation	O
at	O
48	O
h	O
was	O
increased	O
to	O
+	O
/	O
-	O
6	O
%	O
of	O
control	O
by	O
insulin	O
and	O
by	O
+	O
/	O
-	O
13	O
%	O
by	O
IGF	O
-	O
I	O
(	O
both	O
at	O
3	O
nM	O
)	O
.	O

Creatine	B
accumulation	O
at	O
48	O
h	O
was	O
also	O
increased	O
to	O
+	O
/	O
-	O
of	O
control	O
by	O
3,3	B
'	I
,	I
5	I
-	I
triiodothyronine	I
(	O
at	O
microM	O
)	O
and	O
to	O
+	O
/	O
-	O
35	O
%	O
of	O
control	O
by	O
amylin	B
(	O
nM	O
)	O
.	O

As	O
3,3	B
'	I
,	I
5	I
-	I
triiodothyronine	I
,	O
amylin	B
and	O
isoproterenol	B
all	O
stimulate	O
the	O
Na+	O
,	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
,	O
we	O
suggest	O
that	O
they	O
stimulate	O
Na	B
(	I
+	I
)	I
-	O
creatine	B
cotransport	O
indirectly	O
by	O
increasing	O
the	O
transmembrane	O
[	O
Na+	B
]	O
concentration	O
gradient	O
and	O
membrane	O
potential	O
.	O

Replacing	O
dietary	O
palmitic	B
acid	I
with	O
elaidic	B
acid	I
(	O
t	O
-	O
C18	O
:	O
1	O
delta9	O
)	O
depresses	O
HDL	O
and	O
increases	O
CETP	O
activity	O
in	O
cebus	O
monkeys	O
.	O

The	O
question	O
whether	O
dietary	O
trans	O
fatty	O
acids	O
affect	O
lipoprotein	O
metabolism	O
similarly	O
to	O
specific	O
saturated	B
fatty	I
acids	I
was	O
investigated	O
in	O
11	O
normolipemic	O
cebus	O
monkeys	O
by	O
exchanging	O
5	O
%	O
dietary	O
energy	O
(	O
%	O
en	O
)	O
between	O
elaidic	B
(	O
t	O
-	O
C18	O
:	O
1	O
delta9	O
)	O
and	O
palmitic	B
acid	I
(	O
16	O
:	O
0	O
)	O
in	O
two	O
test	O
diets	O
(	O
en	O
fat	O
+	O
mg	O
cholesterol	B
/	O
kcal	O
diet	O
)	O
conforming	O
to	O
the	O
American	O
Heart	O
Association	O
(	O
AHA	O
)	O
Step	O
1	O
guidelines	O
.	O

These	O
were	O
compared	O
with	O
a	O
normal	O
control	O
diet	O
rich	O
in	O
saturated	O
fat	O
and	O
cholesterol	B
(	O
38	O
%	O
en	O
fat	O
+	O
mg	O
cholesterol	B
/	O
kcal	O
diet	O
)	O
.	O

The	O
control	O
diet	O
was	O
fed	O
initially	O
for	O
14	O
wk	O
,	O
followed	O
by	O
each	O
of	O
the	O
the	O
two	O
test	O
diets	O
in	O
a	O
crossover	O
design	O
.	O

Plasma	O
lipid	B
concentrations	O
were	O
determined	O
four	O
times	O
between	O
the	O
6th	O
and	O
14th	O
wk	O
.	O

Turnover	O
studies	O
(	O
using	O
125I	O
-	O
HDL	O
and	O
131I	O
-	O
LDL	O
)	O
were	O
conducted	O
after	O
9	O
wk	O
in	O
each	O
dietary	O
period	O
.	O

Relative	O
to	O
the	O
control	O
diet	O
,	O
both	O
test	O
diets	O
significantly	O
reduced	O
plasma	O
total	O
cholesterol	B
(	O
TC	O
)	O
,	O
HDL	O
cholesterol	B
(	O
HDL	O
-	O
C	O
)	O
and	O
VLDL	O
plus	O
LDL	O
cholesterol	B
(	O
LDL	O
-	O
C	O
)	O
concentrations	O
;	O
triglyceride	B
(	O
TG	B
)	O
concentrations	O
tended	O
to	O
be	O
lower	O
.	O

However	O
,	O
the	O
trans	O
diet	O
resulted	O
in	O
a	O
significantly	O
greater	O
reduction	O
in	O
HDL	O
-	O
C	O
than	O
the	O
palmitate	O
diet	O
(	O
124	O
+	O
/	O
-	O
17	O
,	O
117	O
+	O
/	O
-	O
18	O
and	O
+	O
/	O
-	O
13	O
mg	O
/	O
dL	O
for	O
the	O
control	O
,	O
palmitate	O
and	O
trans	O
diets	O
,	O
respectively	O
)	O
.	O

The	O
palmitate	B
diet	O
significantly	O
decreased	O
the	O
TC	O
/	O
HDL	O
-	O
C	O
ratio	O
by	O
11	O
%	O
when	O
compared	O
with	O
the	O
control	O
diet	O
(	O
1.68	O
+	O
/	O
-	O
0.17	O
vs.	O
1.89	O
+	O
/	O
-	O
0.30	O
)	O
,	O
whereas	O
the	O
trans	O
diet	O
had	O
no	O
effect	O
(	O
1.81	O
+	O
/	O
-	O
0.20	O
vs.	O
1.89	O
+	O
/	O
-	O
0.30	O
)	O
.	O

Kinetic	O
studies	O
revealed	O
that	O
,	O
relative	O
to	O
the	O
control	O
diet	O
,	O
both	O
test	O
diets	O
significantly	O
lowered	O
the	O
LDL	O
apolipoprotein	O
B	O
(	O
apoB	O
)	O
pool	O
size	O
,	O
principally	O
reflecting	O
an	O
increase	O
in	O
the	O
LDL	O
apoB	O
fractional	O
catabolic	O
rate	O
(	O
FCR	O
)	O
related	O
to	O
the	O
reduced	O
cholesterol	O
intake	O
.	O

Between	O
the	O
two	O
test	O
diets	O
,	O
no	O
significant	O
differences	O
in	O
LDL	O
kinetic	O
parameters	O
were	O
observed	O
.	O

Both	O
test	O
diets	O
significantly	O
decreased	O
HDL	O
apoA1	O
concentrations	O
in	O
comparison	O
with	O
the	O
control	O
diet	O
,	O
which	O
was	O
partly	O
explained	O
by	O
an	O
increase	O
in	O
the	O
fractional	O
catabolic	O
rate	O
of	O
HDL	O
.	O

Of	O
the	O
two	O
test	O
diets	O
,	O
the	O
trans	O
diet	O
was	O
associated	O
with	O
a	O
9.5	O
%	O
greater	O
HDL	O
FCR	O
than	O
the	O
palmitate	B
diet	O
(	O
P	O
<	O
0.08	O
)	O
and	O
a	O
significant	O
increase	O
in	O
plasma	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
activity	O
(	O
%	O
transfer	O
114	O
+	O
/	O
-	O
7	O
vs.	O
91	O
+	O
/	O
-	O
7	O
;	O
P	O
<	O
0.03	O
)	O
.	O

Thus	O
,	O
palmitic	B
acid	I
-	O
and	O
elaidic	B
acid	I
-	O
rich	O
diets	O
produced	O
identical	O
effects	O
on	O
LDL	O
metabolism	O
in	O
normocholesterolemic	O
cebus	O
monkeys	O
fed	O
diets	O
with	O
low	O
levels	O
of	O
cholesterol	B
,	O
whereas	O
elaidic	B
acid	I
depressed	O
HDL	O
-	O
C	O
,	O
attributable	O
to	O
both	O
increased	O
CETP	O
activity	O
and	O
HDL	O
clearance	O
.	O

Parenteral	O
hydroxypropyl	B
cyclodextrins	I
:	O
intravenous	O
and	O
intracerebral	O
administration	O
of	O
lipophiles	O
.	O

Hydroxypropyl	B
cyclodextrins	I
are	O
nontoxic	O
carbohydrate	B
derivatives	B
of	O
moderate	O
molecular	O
weight	O
(	O
Da	O
)	O
which	O
form	O
water	O
-	O
soluble	O
complexes	O
with	O
many	O
lipophiles	O
.	O

The	O
fate	O
of	O
hydroxypropyl	B
beta	I
-	I
cyclodextrin	I
alone	O
and	O
in	O
complex	O
with	O
testosterone	B
or	O
cholesterol	B
injected	O
intravenously	O
or	O
intracerebrally	O
into	O
rats	O
was	O
followed	O
.	O

More	O
than	O
of	O
intravenously	O
administered	O
hydroxypropyl	B
beta	I
-	I
cyclodextrin	I
was	O
cleared	O
into	O
urine	O
in	O
4	O
h	O
,	O
as	O
previously	O
described	O
(	O
Monbaliu	O
,	O
J	O
.	O
;	O
Van	O
Beijsterveld	O
,	O
L	O
.	O
;	O
Meuldermans	O
,	O
W	O
.	O
;	O
Szathmary	O
,	O
S	O
.	O
;	O
Haykants	O
,	O
J	O
.	O

Abstracts	O
,	O
5th	O
International	O
Symposium	O
on	O
Cyclodextrins	B
,	O
Paris	O
,	O
;	O
Abstract	O
65	O
)	O
.	O

After	O
the	O
injection	O
of	O
steroids	O
in	O
complex	O
with	O
hydroxypropyl	B
beta	I
-	I
cyclodextrin	I
into	O
the	O
tail	O
vein	O
of	O
rats	O
,	O
the	O
steroid	O
component	O
was	O
released	O
from	O
the	O
complex	O
,	O
before	O
it	O
reached	O
the	O
kidneys	O
;	O
the	O
release	O
occurred	O
mainly	O
into	O
the	O
proteins	O
and	O
lipoproteins	O
of	O
serum	O
.	O

Hydroxypropyl	B
beta	I
-	I
cyclodextrins	I
injected	O
alone	O
into	O
the	O
brain	O
were	O
cleared	O
within	O
less	O
than	O
24	O
h	O
,	O
presumably	O
via	O
the	O
flow	O
of	O
interstitial	O
and	O
cerebrospinal	O
fluids	O
,	O
and	O
eventually	O
were	O
excreted	O
in	O
urine	O
.	O

Testosterone	B
,	O
incorporated	O
in	O
a	O
hydroxypropyl	B
beta	I
-	I
cyclodextrin	I
complex	B
,	O
after	O
intracerebral	O
injection	O
was	O
cleared	O
from	O
the	O
brain	O
even	O
more	O
rapidly	O
than	O
hydroxypropyl	B
beta	I
-	I
cyclodextrin	I
,	O
presumably	O
by	O
crossing	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
later	O
removal	O
to	O
the	O
liver	O
by	O
the	O
specific	O
carrier	O
proteins	O
in	O
serum	O
.	O

Complexed	O
cholesterol	B
,	O
in	O
a	O
similar	O
experiment	O
,	O
was	O
largely	O
retained	O
in	O
the	O
brain	O
and	O
its	O
distribution	O
there	O
was	O
uneven	O
and	O
remained	O
that	O
way	O
for	O
at	O
least	O
3	O
days	O
.	O

It	O
is	O
clear	O
that	O
lipophilic	O
agents	O
,	O
after	O
their	O
incorporation	O
into	O
hydroxypropyl	B
beta	I
-	I
cyclodextrin	I
complexes	B
and	O
subsequent	O
in	O
vivo	O
administration	O
,	O
are	O
rapidly	O
released	O
and	O
exchanged	O
into	O
the	O
plasma	O
.	O

In	O
absence	O
of	O
plasma	O
they	O
enter	O
tissues	O
surrounding	O
the	O
injection	O
site	O
and	O
thus	O
are	O
also	O
promptly	O
transferred	O
into	O
the	O
organism	O
's	O
lipid	B
systems	O
.	O

The	O
manner	O
in	O
which	O
different	O
lipophilic	O
agents	O
are	O
transported	O
in	O
vivo	O
appears	O
not	O
to	O
be	O
greatly	O
affected	O
by	O
their	O
previous	O
complexation	O
;	O
rather	O
hydroxypropyl	B
cyclodextrins	I
just	O
enable	O
their	O
entry	O
in	O
a	O
larger	O
amount	O
and	O
in	O
an	O
exchangeable	O
,	O
nonaggregated	O
form	O
.	O

